Date: 10/6/11 - wistar.org 10.6.11.pdf · Meenhard Herlyn, D.V.M., D.Sc. 2 Cancer Center, Houston, TX 1989-1991 Wistar Institute Associate Professor of Dermatology and Wistar Institute

Meenhard Herlyn, D.V.M., D.Sc.

1

Meenhard Herlyn, D.V.M, D.Sc. Curriculum Vitae

Date: 10/6/11 Home Address: 1223 Knox Road Wynnewood, PA 19096 Office Address: The Wistar Institute 3601 Spruce Street Philadelphia, PA 19104 USA Tel. 215-898-3950 Fax 215-898-0980 Email: [email protected] Web: http://www.wistar.org/herlyn Education: 1970 D.V.M, Veterinary Medical School, Hannover, Germany 1976 D.Sc., Medical Microbiology, University of Munich, Munich, Germany Postgraduate Training and Fellowship Appointments: 1971-1972 Fellowship in Immunology and Virology, University of Munich,

Munich, Germany 1972-1976 Assistant at the Institute of Medical Microbiology, Infectious and

Epidemic Deseases, Veterinary Faculty, Maximilliam University, Munich, Germany

1976-1979 Associate Scientist, The Wistar Institute, Philadelphia, PA 1979-1981 Research Associate, The Wistar Institute 1981-1985 Assistant Professor, The Wistar Institute 1986-1990 Associate Professor, The Wistar Institute 1991- present Professor, The Wistar Institute 1991-1993 Chairman, Program of Experamental Therapeutics, The Wistar

Institute 1993-1998 Chairman, Program of Molecular and Cellular Biology, The

Wistar Institute 1998-2002 Chairman, Tumor Biology Program, The Wistar Institute 2002-present Leader, Molecular and Cellular Oncogenesis Program, The

Wistar Institute 2008-2011 Associate Director for Translational Research, The Wistar

Institute 2010-present Director, Melanoma Research Center 2011-present Caspar Wistar Professor in Melanoma Research Faculty Appointments: 1982-1996 Consultant, Adjunct Associate Professor of Gynecology,

Adjunct Professor of Gynecology, Dept. of Gynecology, Division of Surgery, University of Texas, M.D. Anderson


2

Cancer Center, Houston, TX 1989-1991 Wistar Institute Associate Professor of Dermatology and Wistar

Institute Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

1989-present Member, Cellular and Molecular Biology Graduate Program (CAMB), University of Pennsylvania

1991- present Member, University of Pennsyvlania Comprehensive Cancer Center

1992-present Wistar Institute Professor of Dermatology and Wistar Instituate Professor of Pathology and Laboratory Medicine, University of Pennsylvania

1995-2002 Member, Institute for Human Gene Therapy, University of Pennsylvania

2007-present Member, Bioengineering Graduate Group, University of Pennsylvania

Awards & Honors: 2004 Wings of Hope, Melanoma Research Foundation Award 2004 Diana Ashby Award for Excellence in Melanoma Research 2005 American Skin Association Annual Skin Cancer/Melanoma

Achievement Award 2006 Scientific Research Award for Outstanding Contributions in

Melanoma Research, American Cancer Society, Southeast Region, Pennsylvania Division

2006 7th Annual Wallace H. Clark, Jr., M.D. Lectureship in Cutaneous Oncology, University of Pennsylvania, Philadelphia, PA

2007 Pan American Pigment Cell Society Achievement Award 2007 Lifetime Achievement Award in Melanoma Research, Society

of Melanoma Research 2008 28th Alfred-Marchioni Memorial Award, Hamburg, Germany 2008 Joseph-von-Plenck Award, Austrian Society for Dermatology

and Venerology, Vienna Austria 2010 Award for Lifetime Achievement in Melanoma Research,

Society for Melanoma Research Memberships in Professional and Scientific Societies (including offices held): 1982-present American Association for Cancer Research 1996-2002, Pennsylvania Steering Committee 1997, Program Committee Chair, Biology 2004-2005, Stem Cell Initiative 1984-2010 American Association for Investigative Pathology 1995-present Society for Investigative Dermatology 1999-present Pan American Society for Pigment Cell Research 1999-2002, Council Member 1999-2002, Melanoma Group Chair 2000-2002, Membership Committee 1999-present International Federation of Pigment Cell Societies 1999-2003, Special Interest Group on ‘Biology of Melanoma’

Chair


3

1985-present American Association for the Advancement of Science 2000-present Metastasis Research Society 2004-present Society for Melanoma Research 2004-2007, Founder and President 2004-2007, Ex officio member of Exeutive Committee, Steering

Committee (Chair), Meeting Committee, Finance Committee, Election Committee, Membership Committee

2007-2010, Past President, Member Steering Committee 2006-present 2010-present

Society for Stem Cell Research American Society for Clinical Oncology

Editorial Positions: 1986-1988 Editorial Board, The Journal of Clinical Laboratory Analysis 1990-present Associate Editor, Melanoma Research 1992-1998 Editorial Board, Cell Growth and Differentiation 1994-1999 Associate Editor, Pigment Cell Research 1995-2003 Associate Editor, Journal of Experimental Therapeutics and

Oncology 1995-2002 Editorial Board, Pathology Oncology Research 1997-2004 Editorial Board, American Journal of Pathology 1998-2000 Editorial Board, Tumor Targeting 2000-2007 Editorial Board, Cancer Research 2001-present Editorial Board, Cancer Biology and Therapy 2002-present Editorial Board, Cancer and Metastasis Review, 2005 Guest

Editor 2002-2007 Associate Editor, Journal of Investigative Dermatology 2005-present Associate Editor, Pigment Cell and Melanoma Research 2005-present Editorial Board, International Journal of Cancer 2007-present Section Editor, Journal of Investigative Dermatology 2007-present Scientific Advisory Board, Journal of Cell Communication and

Signaling 2007-present Editorial Board, Open Dermatology Journal 2008-present Editorial Board, Journal of Oncology 2008-present Editorial Board, Experimental Dermatology 2009-present Editorial Board, Genes & Cancer 2010-2011 Editorial Board, PLoS One Reviewer, with major support from laboratory members, of 125 manuscripts in 2004, 154 in 2005, 184 in 2006, 176 in 2007, 118 in 2008, 111 in 2009 for: American Journal of Pathology, Archives of Dermatology, Cancer, Cancer Cell, Cancer Research, Cell, Clinical Cancer Research, Experimental Cell Research, International Journal of Cancer, Journal of Cell Science, Journal of Clinical Investigations, Journal of Investigative Dermatology, Journal of Immunology, Journal of Experimental Medicine, Laboratory Investigation, Melanoma Research, Molecular Carcinogenesis, Nature, Nature Cell Biology, Nature Medicine, Nature Review Cancer, Oncogene, Pigment Cell Melanoma Research, Proceedings National Academy of Sciences (USA), Science.


4

Lectures by Invitations (past 5 years): 2007 Jan. 12 Moffitt Cancer Center, Tampa, FL Febr. 9 Jefferson University, Phildelphia, PA Febr. 19 Adelson Foundation, Las Vegas, NV Febr. 28 NCI Strategic Action Plan for Melanoma Research, Bethesda,

MD, co-chair April 14 AACR Annual Meeting, Los Angeles, CA May 4 Atlantic Dermatological Society, Philadelphia, PA June 25 Temple University, Philadelphia, PA June 27 Darthmouth Medical Collegue, Darthmouth, NH July 9 SPORE Workshop, Baltimore, MD July 29 Gordon Research Conference, Brynt University, Smithville, RI Oct.1/5 21st World Congress of Dermatology, Buenos Aires, Argentina,

Keynote Lecture Oct. 16 EUROSKIN, Hamburg, Germany Oct. 18 UV-radiation-induced disease: UVA and UVB, Stockholm,

Sweden Oct. 27 Tumor-host interactions and angiogenesis, Lausanne,

Switzerland Nov. 1 Society for Melanoma Research, New York City, NY Nov. 13 MedImmune, Gaithersburg, MD Nov. 16 University of Colorado, Denver, CO Nov. 26 Department of Pharmacology, University of Pennsylvania,

Philadelphia, PA Nov. 27 Mt. Sinai, New York City, NY Dec. 1 International Workshop on Cancer Stem Cells, Milano, Italy Dec. 3 Universita Vita e Salute, San Raffaele, Italy Dec. 14 National Institutes of Health, Baltimore, MD 2008 Jan. 8 Abramson Cancer Center, University of Pennsylvania,

Philadelphia, PA Jan. 23 L’Oreal, Paris, France Jan. 26 University of Hamburg, Hamburg, Germany, Honorary Lecture March 3 Columbia University, New York, NY March 7 Glaxo Smith Kline, Collegeville, PA March 19 University of North Carolina, Chapel Hill, NC May 10 Society for Melanoma Research, Sapporo, Japan May 22 University of California San Francisco, San Francisco, CA June 9 Moffitt Cancr Center, Tampa, FL Sept. 29 University of Tuebingen, Germany Oct. 6 Notch and Cancer, Athens, Greece Oct. 9 German Society of Gene Therapy Symposium, Berlin, Germany Nov. 30 Austrian Society of Dermatology, Vienna, Austria, Honorary

Lecture Dec. 11 Univesity of Tennessee, Memphis, TN 2009

Febr. 23

Melanoma Research Allicance

April 18 American Association for Cancer Research, Denver, CO April 29 University of Wisconsin, Madison, WI May 12 World Congress of Melanoma, Vienna, Austria, Keynote lecture May 20 Austrialian Congress of Dermatology, Brisbane, Australia,

Honorary lecture May 27 Rutgers University, Cancer Center Retreat, Keynote lecture


5

June 23 University of Heidelberg, Germany July 17 Mayo Clinic, Rochester, MN Sept. 18 NCI, Frederick, MD Oct. 9 European Academy for Dermatology and Venerology, Berlin,

Germany Nov. 2 4th InT. Congress Society for Melanoma Research, Boston, MA Nov.18 M.D. Anderson Cancer Center, Houston, TX Nov. 20 Cancer Therapy, Havanna, Cuba 2010 Jan. 11 University of Vienna, Vienna, Austria Jan 14 L'Oreal, Paris, France Febr. 23 University of North Carolina, Chapel Hill, NC March 2 University of Pittsburgh, Pittsburgh, PA March 31 University of California at Irvine, Irvine, Ca April 30 Moffitt Cancer Center, Tampa, FL May 28 Schering-Plough, Kenilworth, NJ June 2 MD Anderson Cancer Center, SPORE Symposium, Houston, TX June 24 GENOMel, University of Leeds, Leeds, GB June 26 Human skin carcinogenesis symposium, Collegeville, PA August 2 Roswell Park Memorial Institute, Buffalo, NY Sept. 12 AACR TME and Metastasis, Philadelphia, PA Nov. 2 Centenary Institute, University of Sydney, Sydney, Australia Nov. 5 SMR International Conference, Sydney, Australia Nov. 9 Melanoma Symposium, Western Australia Institute for Medical

Research, Perth, Australia Dec. 14 University of Ohio, Cincinnatti, OH 2011 Jan. 12 M.D. Anderson Cancer Center, Science Park, TX Jan. 28 L’Oreal, Paris, France Febr. 2 Adelson Medical Research Foundation, Las Vegas, NV Febr. 18 Melanoma Research Alliance, Washington, DC, Session Chair March 7 AACR Special Conference on Stem cells, differentiations and

Cancer, Vancouver, Canada, Session Chair March 23 Banbury Meeting on Curing Melanoma, Cold Spring Harbor

Laboratory, NY, Session Chair April 2/4 AACR Annual meeting, Orlando, FL April 27 CSHL Symposium on Tumor microenvironment, Cold Spring

Harbor, NY May 5 Tetralogic, Malvern, PA May 25 World Congress of Dermatology, Seoul, Korea

June 27 Engineered tissue models for environmental health science research, NIEHS, Research Triangle Park, Chapel Hill, NC

July 10 Eurpean Post-ASCO meeting, Munich, Germany Advisory Roles (Last 5 years): 1999-2009 The Noreen O’Neill Foundation for Melanoma Resarch, Member of

Board, Scientific Advisory Committee Chair

2004-2007 SPORE in Skin Cancer, E. Grimm, PI, MD Anderson Cancer Center, advisor

2004-2007 SPORE in Breast Cancer, C. Jordan, PI, Fox Chase Cancer Center,


6

advisor

2004-2008 COBRE Grant, R. Miles, PI, Marshal University, Huntington, VW, advisor

2004-2007 National Disease Research Interchange (NDRI), Board of Directors, Cancer Advsiory Committee, Chair

2005 Feb., June, Oct., NCI Study Sections, Tumor Microenvironment (TME), Chair March, NCI Special Emphasis Panels (2), Chair June, NCI, P01 Cluster Review, ad hoc July, NCI Special Emphasis Panels (3), Chair Sept., Melanoma Research Foundation Nov., NCI RAIDD Program, ad hoc Nov. NIAMS, SDRC, ad hoc Feb-Dec. Reviews for Cancer Panels in Netherlands, Austria, Italy, Israel, Canada, Australia, Irelandq

2005-2010 Scientific Advisory Board, Biomega Laboratores, Inc., New York, NY, Member

2006 2006-2007

Feb., June, SCI Study Sections, Tumor Microenvironment (TME), Chair Feb-Dec., Reviews for Cancer Panels in Italy, Austria, Canada, Switzerland, Great Britian, Germany, Ireland, New Zealand Sept., NCI, X02, Roadmap to Interdisciplinary Research Collaborations, Special Emphasis Panel NIH, Neurogenesis and Cell Fate Study Section (NCF), ad hoc Scientific Advisory Board, GenoMEL (Melanoma Genetics consortium) External Advisor PO1, The systems response to DNA damage suppresses environmental melanomagenesis, W. Kaufman, PI, University of North Carolina, Chapel Hill, NC

2007 2007-2010

Feb, NCI Study Section, Tumor Microenvironment (TME), ad hoc Feb, June, Oct, SPORE Special Emphasis Panel NIH Loan Repayment Program (LRP), Special Emphasis Panel PO1, PI Shelley Berger, “Ubinquination in aging”, Advisor Melanoma Molecular Map Progect (MMMP), Advisor Donald A. Adam Comprehensive Melanoma Research Center, External Advisory Board Member, Moffitt Cancer Center and Resarch Institute, Tampa FL The Melanoma Researh Foundation (MRF), Scientific Advisory Committee, Chair

2008 Feb, NCI Study Section, Tumor Microenvironment (TME), ad hoc Nov., NIH Study Section, Skin Disease Research Center, ad hoc Jan., June, External Advisor, SPORE on Ovarian Cancer (PI: M. Seiden), Fox Chase Cancer Center, Philadelphia, PA Feb., SPORE Special Emphasis Panel

Febr-Dec, Grant reviews for funding agencies in Austria, New


7

Zealand, Australia, Poland, Israel, Ireland

2008-2011 MRF, Board of Managers, Member

2009 Jan., External Advisory, Southwestern Melanoma SPORE, Denver, CO Jan., External Advisor, PO1 Biotherapy of Metastatic Melanoma: Biology and Systemic Delivery of MDA7/IL-24, (E. Grimm, PI), M.D. Anderson Cancer Center, Houston, TX Febr., Oct., NCI Study Sections, Tumor Microenvironment (TME), ad hoc May, NCI Intramural Review, Laboratory of Cancer Prevention July, NCI, Stage II Challenge Grant review committee, ad hoc Oct., Utah Skin SPORE, External Advisor Febr.-Dec, Grant reviews for funding agencies in Netherlands, Austria, Australia, Germany, Israel, Great Britian Australia, Germany, Israel, Great Britain

2010 Advisory Board, Joanna M. Nikolay Melanoma Foundation NDRI, Board of Directors, Chair NCI, Febr., Oct., TME Study Section, Member, NCI, Special Emphasis Panel, Chair MRA, Grant Review Committee, co-Chair Roche, Washington, DC, advisor Moffitt Cancer Center, SPORE advisor, Tampa, FL MRF Breakthrough Consortium, Board of Directors MRF Breakthrough Consortium, Secretary Treasurer

2011 Melanoma Research Alliance, co-chair Scientific Review Committeee June, Tumor Microenvironment Network Study Section, NCI, chair Sept., SPORE study section, adhoc

Oct., TME NCI Study Section, member Funding: Targeted therapies in melanoma Principal Investigator: Meenhard Herlyn Agency: National Cancer Institute Type: PO1 (CA114046-03) Years 1-5, Period: May 16, 2008 to May 15, 2013 Subproject on grant: Targeting the MAPK and PI3K pathways in melanoma Human Melanoma: Etiology, Progression, and Therapy Principal Investigator: Meenhard Herlyn Agency: NIH/NCI Type: P01-Program Project (CA25874), Years 30-34, Period: May 1, 2011 to April 30, 2016 Subproject on grant: Cellular mechanisms of therapy resistance 3D Human Skin Models Principal Investigator: Meenhard Herlyn Agency: NIH/NCI Type: RC1 (ES018210)


8

Period: September 21, 2009 to July 31, 2012 Biology of Melanoma metastasis Principal Investigator: Meenhard Herlyn Agency: National Cancer Institute Type: R01 (CA47159) Years 21-25, 2011-2016 Cell-cell Communication during melanoma progression Principal Investigator: Meenhard Herlyn Agency: National Cancer Institute Type: R01 (CA76674) Years 15-19, Period: April 1, 2011 to March 31, 2016 Mechanisms of esophageal carcinogenesis Principal Investigator: Anil Rustgi, Co-Principal Investigator: Meenhard Herlyn Agency: NIH/NCI Type: P01-CA098101 Years 6-10, Period: July 1, 2009 – June 30, 2014 Subproject on grant: The tumor microenvionment in human esophageal squamous cell carcinoma Core Activities: 1. Administrative Core A for Human Melanoma – Etiology, Progression & Therapy (CA025874), 2. Administrative Core A for Targeted Therapies in Melanoma (CA114046) 3. Cell Biology Core C for Targeted Therapies in Melanoma (CA114046) 2008-2011: Six sponsored agreements with industry.


9

Bibliography: Research Publications, peer-reviewed: 1. Buschmann, H., Herlyn, M.: Stimulation of phagocytic activity by dextran. Z Immunitatsforsch Exp

Klin Immunol 143:209-210, 1972. PMID4282799 2. Mayr, A., Streitferdt, U., Herlyn, M., Jaeger, O.: Vaccination of dogs against rabies. Die

Kleintierpraxis 18:91-96, 1973. 3. Danner, K., Herlyn, M., Gerbermann, H., Mayr, A.: Oral immunization against pox. 5.

Effectiveness of drinking water vaccination against fowl pox. Zentralbl Veterinärmed B 22:274-284, 1975. PMID169653

4. Mahnel, H., Herlyn, M.: Stability of Teschen, HCC, ND and vaccinia viruses against 5 disinfectants. Zentralbl Veterinärmed B 23:403-411, 1976. PMID183417

5. Mahnel, H., Ottis, K., Herlyn, M.: Stability in drinking and surface water of nine virus species from different genera (author’s transl). Zentralbl Bakteriol [Orig B] 164:64-84, 1977. PMID14460

6. Danner, K., Luthgen, K., Herlyn, M., Mayr, A.: Comparative studies on the demonstration and formation of serum antibodies against the Borna virus. Zentralbl Veterinärmed B 25:345-355, 1978. PMID358683

7. Koprowski, H., Steplewski, Z., Herlyn, D., Herlyn, M.: Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A 75:3405-3409, 1978. PMID80012

8. Herlyn, D., Herlyn, M., Steplewski, Z., Koprowski, H.: Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9:657-659, 1979. PMID499332

9. Herlyn, M., Steplewski, Z., Herlyn, D., Koprowski, H.: Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 76:1438-1442, 1979. PMID286328

10. Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., Fuhrer, P.: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957-971, 1979. PMID94699

11. Steplewski, Z., Herlyn, M., Herlyn, D., Clark, W.H., Koprowski, H.: Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol 9:94-96, 1979. PMID374094

12. Herlyn, M., Clark, W.H., Jr., Mastrangelo, M.J., Guerry, D.P.t., Elder, D.E., LaRossa, D., Hamilton, R., Bondi, E., Tuthill, R., Steplewski, Z., Koprowski, H.: Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res 40:3602-3609, 1980. PMID6159966

13. Herlyn, D.M., Steplewski, Z., Herlyn, M.F., Koprowski, H.: Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40:717-721, 1980. PMID7471090

14. Wittek, R., Herlyn, M., Schumperli, D., Bachmann, P.A., Mayr, A., Wyler, R.: Genetic and antigenic heterogeneity of different parapoxvirus strains. Intervirology 13:33-41, 1980. PMID6153643

15. Koprowski, H., Herlyn, M., Steplewski, Z., Sears, H.F.: Specific antigen in serum of patients with colon carcinoma. Science 212:53-55, 1981. PMID6163212

16. Mayr, A., Herlyn, M., Mahnel, H., Danco, A., Zach, A., Bostedt, H.: Control of ecthyma contagiosum (pustular dermatitis) of sheep with a new parenteral cell culture live vaccine. Zentralbl Veterinarmed B 28:535-552, 1981. PMID7331595

17. Sears, H.F., Herlyn, D., Herlyn, M., Grotzinger, P.J., Steplewski, Z., Gerhard, W., Koprowski, H.: Ex vivo perfusion of a tumor-containing colon with monoclonal antibody. J Surg Res 31:145-150, 1981. PMID6790874

18. Steplewski, Z., Chang, T.H., Herlyn, M., Koprowski, H.: Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res 41:2723-2727, 1981. PMID7248940


10

19. Atkinson, B.F., Ernst, C.S., Herlyn, M., Steplewski, Z., Sears, H.F., Koprowski, H.: Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 42:4820-4823, 1982. PMID6751528

20. Brockhaus, M., Magnani, J.L., Herlyn, M., Blaszczyk, M., Steplewski, Z., Koprowski, H., Ginsburg, V.: Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors. Arch Biochem Biophys 217:647-651, 1982. PMID7138030

21. Herlyn, M., Sears, H.F., Steplewski, Z., Koprowski, H.: Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 2:135-140, 1982. PMID7068815

22. Herlyn, M., Steplewski, Z., Atkinson, B.F., Ernst, C.S., Koprowski, H.: Comparative study of the binding characteristics of monoclonal antimelanoma antibodies. Hybridoma 1:403-411, 1982. PMID6765323

23. Sears, H.F., Herlyn, M., Del Villano, B., Steplewski, Z., Koprowski, H.: Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol 2:141-149, 1982. PMID7068816

24. Sears, H.F., Herlyn, D., Herlyn, M., Steplewski, Z., Grotzinger, P., Koprowski, H.: Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer 49:1231-1235, 1982. PMID7059945

25. Thompson, J.J., Herlyn, M.F., Elder, D.E., Clark, W.H., Steplewski, Z., Koprowski, H.: Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol 107:357-361, 1982. PMID6177248

26. Thompson, J.J., Herlyn, M.F., Elder, D.E., Clark, W.H., Steplewski, Z., Koprowski, H.: Expression of DR antigens in freshly frozen human tumors. Hybridoma 1:161-168, 1982. PMID6208123

27. Folberg, R., Donoso, L.A., Herlyn, M.F., Koprowski, H.: Antigens in ocular and cutaneous melanomas. Am J Ophthalmol 96:394-395, 1983. PMID6351625

28. Hansson, G.C., Karlsson, K.A., Larson, G., McKibbin, J.M., Blaszczyk, M., Herlyn, M., Steplewski, Z., Koprowski, H.: Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens. Characterization by antibody binding to glycosphingolipids in a chromatogram binding assay. J Biol Chem 258:4091-4097, 1983. PMID6833243

29. Herlyn, M., Herlyn, D., Elder, D.E., Bondi, E., LaRossa, D., Hamilton, R., Sears, H.F., Balaban, G., Guerry, D.t., Clark, W.H., Kaprowski, H.: Phenotypic characteristics of cells derived from precursors of human melanoma. Cancer Res 43:5502-5508, 1983. PMID6616481

30. Herlyn, D., Powe, J., Alavi, A., Mattis, J.A., Herlyn, M., Ernst, C., Vaum, R., Koprowski, H.: Radioimmunodetection of human tumor xenografts by monoclonal antibodies. Cancer Res 43:2731-2735, 1983. PMID6342757

31. Herlyn, M., Steplewski, Z., Herlyn, D., Clark, W.H., Jr., Ross, A.H., Blaszczyk, M., Pak, K.Y., Koprowski, H.: Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Invest 1:215-224, 1983. PMID6667406

32. Herlyn, M., Blaszczyk, M., Sears, H.F., Verrill, H., Lindgren, J., Colcher, D., Steplewski, Z., Schlom, J., Koprowski, H.: Detection of carcinoembryonic antigen and related antigens in sera of patients with gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays. Hybridoma 2:329-339, 1983. PMID6205981

33. Mach, J.P., Chatal, J.F., Lumbroso, J.D., Buchegger, F., Forni, M., Ritschard, J., Berche, C., Douillard, J.Y., Carrel, S., Herlyn, M., Stepiewski, Z, Koprowski, H.: Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 43:5593-5600, 1983. PMID6616486

34. Ross, A.H., Cossu, G., Herlyn, M., Bell, J.R., Steplewski, Z., Koprowski, H.: Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys 225:370-383, 1983. PMID6614928

35. Steplewski, Z., Herlyn, M., Blaszczyk, M., Koprowski, H.: A simple procedure for determining Lewis phenotypes in human saliva. J Immunol Methods 62:73-78, 1983. PMID6348171


11

36. Zehngebot, L.M., Alexander, M.A., Guerry, D.t., Cines, D.B., Mitchell, K., Herlyn, M.: Functional consequence of variation in melanoma antigen expression. Cancer Immunol Immunother 16:30-34, 1983. PMID6605801

37. Atkinson, B., Ernst, C.S., Ghrist, B.F., Herlyn, M., Blaszczyk, M., Ross, A.H., Herlyn, D., Steplewski, Z., Koprowski, H.: Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res 44:2577-2581, 1984. PMID6722794

38. Balaban, G., Herlyn, M., Guerry, D.t., Bartolo, R., Koprowski, H., Clark, W.H., Nowell, P.C.: Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 11:429-439, 1984. PMID6584203

39. Blaszczyk, M., Hansson, G.C., Karlsson, K.A., Larson, G., Stromberg, N., Thurin, J., Herlyn, M., Steplewski, Z., Koprowski, H.: Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies. Arch Biochem Biophys 233:161-168, 1984. PMID6465894

40. Blaszczyk, M., Pak, K.Y., Herlyn, M., Lindgren, J., Pessano, S., Steplewski, Z., Koprowski, H.: Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies. Cancer Res 44:245-253, 1984. PMID6360346

41. Donoso, L.A., Folberg, R., Angiolillo, P., Herlyn, M.: A 19-9 monoclonal antibody study of adenocarcinoma metastatic to the choroid. Am J Ophthalmol 98:815-816, 1984. PMID6507563

42. Ernst, C., Thurin, J., Atkinson, B., Wurzel, H., Herlyn, M., Stromberg, N., Civin, C., Koprowski, H.: Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human tissues. Am J Pathol 117:451-461, 1984. PMID6507589

43. Ernst, C., Atkinson, B., Wysocka, M., Blaszczyk, M., Herlyn, M., Sears, H., Steplewski, Z., Koprowski, H.: Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest 50:394-400, 1984. PMID6368970

44. Guerry, D.t., Alexander, M.A., Herlyn, M.F., Zehngebot, L.M., Mitchell, K.F., Zmijewski, C.M., Lusk, E.J.: HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest 73:267-271, 1984. PMID6606651

45. Herlyn, M., Sears, H.F., Verrill, H., Koprowski, H.: Increased sensitivity in detecting tumor-associated antigens in sera of patients with colorectal carcinoma. J Immunol Methods 75:15-21, 1984. PMID6512262

46. Herlyn, D., Herlyn, M., Ross, A.H., Ernst, C., Atkinson, B., Koprowski, H.: Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 73:157-167, 1984. PMID6491298

47. Herlyn, M., Lange, B., Bennicelli, J., Blaszczyk, M., Guerry, D.t., Koprowski, H.: Increased levels of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia. Leuk Res 8:323-334, 1984. PMID6431198

48. Herlyn, M., Shen, J.W., Sears, H.F., Civin, C.I., Verrill, H.L., Goldberg, E.M., Koprowski, H.: Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants. Clin Exp Immunol 55:23-35, 1984. PMID6198117

49. Miller, S.L., Pleasure, D., Herlyn, M., Atkinson, B., Ernst, C., Tachovsky, T.G., Baird, L.: Production and characterization of monoclonal antibodies to peripheral and central nervous system myelin. J Neurochem 43:394-400, 1984. PMID6204014

50. Pak, K.Y., Blaszczyk, M., Herlyn, M., Steplewski, Z., Koprowski, H.: Identification and isolation of Lewis blood group antigens from human saliva using monoclonal antibodies. Hybridoma 3:1-10, 1984. PMID6469267

51. Pegg, A.E., Seely, J.E., Persson, L., Herlyn, M., Ponsell, K., O’Brien, T.G.: Studies of mammalian ornithine decarboxylase using a monoclonal antibody. Biochem J 217:123-128, 1984. PMID6421279

52. Ross, A.H., Grob, P., Bothwell, M., Elder, D.E., Ernst, C.S., Marano, N., Ghrist, B.F., Slemp, C.C., Herlyn, M., Atkinson, B., Koprowski, H.: Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A 81:6681-6685, 1984. PMID6093111


12

53. Ross, A.H., Herlyn, M., Ernst, C.S., Guerry, D., Bennicelli, J., Ghrist, B.F., Atkinson, B., Koprowski, H.: Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies. Cancer Res 44:4642-4647, 1984. PMID6380710

54. Verrill, H., Goldberg, M., Kovac, G., Atkinson, B., Herlyn, M.: Evaluation of monoclonal antibody to 19-9 antigen as a potential screening technique for colorectal cancer in a high-risk population. Prog Clin Biol Res 156:107-114, 1984. PMID6382320

55. Atkinson, B., Ernst, C.S., Ghrist, B.F., Ross, A.H., Clark, W.H., Herlyn, M., Herlyn, D., Maul, G., Steplewski, Z., Koprowski, H.: Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma 4:243-255, 1985. PMID4043988

56. Blaszczyk, M., Pak, K.Y., Herlyn, M., Sears, H.F., Steplewski, Z.: Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S A 82:3552-3556, 1985. PMID2582419

57. Donoso, L.A., Folberg, R., Edelberg, K., Arbizo, V., Atkinson, B., Herlyn, M.: Tissue distribution and biochemical properties of an ocular melanoma-associated antigen. J Histochem Cytochem 33:1190-1196, 1985. PMID3905953

58. Folberg, R., Donoso, L.A., Atkinson, B.F., Ernst, C.S., Herlyn, M., Arbizo, V.V.: An antimelanoma monoclonal antibody and the histopathology of uveal melanomas. Arch Ophthalmol 103:275-279, 1985. PMID2579631

59. Herlyn, M., Thurin, J., Balaban, G., Bennicelli, J.L., Herlyn, D., Elder, D.E., Bondi, E., Guerry, D., Nowell, P., Clark, W.H., Koprowski, H.: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670-5676, 1985. PMID4053039

60. Herlyn, M., Blaszczyk, M., Bennicelli, J., Sears, H.F., Ernst, C., Ross, A.H., Koprowski, H.: Selection of monoclonal antibodies detecting serodiagnostic human tumor markers. J Immunol Methods 80:107-116, 1985. PMID3859550

61. Herlyn, M., Guerry, D., Koprowski, H.: Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol 134:4226-4230, 1985. PMID2985706

62. Herlyn, D., Herlyn, M., Steplewski, Z., Koprowski, H.: Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol 92:105-114, 1985. PMID4075410

63. Herlyn, D., Powe, J., Ross, A.H., Herlyn, M., Koprowski, H.: Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells. J Immunol 134:1300-1304, 1985. PMID3965572

64. Herlyn, M., Balaban, G., Bennicelli, J., Guerry, D.t., Halaban, R., Herlyn, D., Elder, D.E., Maul, G.G., Steplewski, Z., Nowell, P.C.: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74:283-289, 1985. PMID3856042

65. Koprowska, I., Zipfel, S.A., Himes, T.R., Herlyn, M.: Common antigenic sites on exfoliated cells derived from cervical carcinoma and in tumor cells of nonuterine origin as demonstrated by monoclonal antibodies in immunoperoxidase assay. Cancer Res 45:5964-5968, 1985. PMID2414003

66. Koprowski, H., Herlyn, M., Balaban, G., Parmiter, A., Ross, A., Nowell, P.: Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 11:297-302, 1985. PMID2988138

67. Matera, L., Francis, M.K., Herlyn, M., Trucco, M., Santoli, D.: Generation of natural killer-like activity in mixed lymphocyte-tumor cell cultures. I. Role of HLA-DR antigens as stimulatory molecules. Nat Immun Cell Growth Regul 4:90-102, 1985. PMID3160934

68. Sears, H.F., Shen, J.W., Herlyn, M., Atkinson, B., Engstrom, P.F., Koprowski, H.: Circulating tumor markers and assessment of response to intrahepatic chemotherapy of colon carcinoma. Am J Clin Oncol 8:108-117, 1985. PMID2929709

69. Thurin, J., Herlyn, M., Hindsgaul, O., Stromberg, N., Karlsson, K.A., Elder, D., Steplewski, Z., Koprowski, H.: Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. J Biol Chem 260:14556-14563, 1985. PMID4055789


13

70. Balaban, G.B., Herlyn, M., Clark, W.H., Jr., Nowell, P.C.: Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet 19:113-122, 1986. PMID3940171

71. Donoso, L.A., Felberg, N.T., Edelberg, K., Borlinghaus, P., Herlyn, M.: Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease. J Immunoassay 7:273-283, 1986. PMID3805289

72. Ernst, C.S., Shen, J.W., Litwin, S., Herlyn, M., Koprowski, H., Sears, H.F.: Multiparameter evaluation of the expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J Natl Cancer Inst 77:387-395, 1986. PMID3461200

73. Ernst, C.S., Sears, H.F., Herlyn, M., Herlyn, D., Steplewski, Z., Koprowski, H.: Detection of murine immunoglobulin in human tissues following therapeutic infusion of monoclonal antibody. Hybridoma 5 Suppl 1:S79-86, 1986. PMID3527948

74. Ernst, C.S., Atkinson, B., Chianese, D., Peters, J., Perry, M., Herlyn, M., Koprowski, H.: Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Appl Pathol 4:115-124, 1986. PMID2885017

75. Herlyn, D., Powe, J., Munz, D.L., Alavi, A., Herlyn, M., Meinken, G.E., Srivastava, S.C., Koprowski, H.: Radioimmunodetection of human tumor xenografts by monoclonal antibody F(ab’)2 fragments. Int J Rad Appl Instrum B 13:401-405, 1986. PMID3793494

76. Koprowska, I., Zipfel, S., Ross, A.H., Herlyn, M.: Development of monoclonal antibodies that recognize antigens associated with human cervical carcinoma. Acta Cytol 30:207-213, 1986. PMID3521172

77. Parmiter, A.H., Balaban, G., Herlyn, M., Clark, W.H., Jr., Nowell, P.C.: A t(1;19) chromosome translocation in three cases of human malignant melanoma. Cancer Res 46:1526-1529, 1986. PMID3943110

78. Rakowicz-Szulczynska, E.M., Rodeck, U., Herlyn, M., Koprowski, H.: Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci U S A 83:3728-3732, 1986. PMID3012531

79. Steplewski, Z., Herlyn, D., Lubeck, M., Kimoto, Y., Herlyn, M., Koprowski, H.: Mechanisms of tumor growth inhibition. Hybridoma 5 Suppl 1:S59-64, 1986. PMID3744386

80. Thurin, J., Thurin, M., Herlyn, M., Elder, D.E., Steplewski, Z., Clark, W.H., Jr., Koprowski, H.: GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 208:17-22, 1986. PMID3533633

81. Westermark, B., Johnsson, A., Paulsson, Y., Betsholtz, C., Heldin, C.H., Herlyn, M., Rodeck, U., Koprowski, H.: Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A 83:7197-7200, 1986. PMID3020539

82. Basu, A., Murthy, U., Rodeck, U., Herlyn, M., Mattes, L., Das, M.: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res 47:2531-2536, 1987. PMID2436750

83. Guerry, D.t., Alexander, M.A., Elder, D.E., Herlyn, M.F.: Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol 139:305-312, 1987. PMID3108402

84. Herlyn, M., Rodeck, U., Mancianti, M., Cardillo, F.M., Lang, A., Ross, A.H., Jambrosic, J., Koprowski, H.: Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res 47:3057-3061, 1987. PMID3034401

85. Menssen, H.D., Herlyn, M., Rodeck, U., Koprowski, H.: Rapid dissociation of adherent human tumor cells by ultrasound. J Immunol Methods 104:1-6, 1987. PMID3316390

86. Murthy, U., Basu, A., Rodeck, U., Herlyn, M., Ross, A.H., Das, M.: Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252:549-560, 1987. PMID2434025

87. Ordonez, N.G., Freedman, R.S., Herlyn, M.: Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol 26:1-10, 1987. PMID2431961


14

88. Rodeck, U., Herlyn, M., Koprowski, H.: Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem 35:315-320, 1987. PMID2831241

89. Rodeck, U., Herlyn, M., Menssen, H.D., Furlanetto, R.W., Koprowski, H.: Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40:687-690, 1987. PMID3316051

90. Rodeck, U., Herlyn, M., Leander, K., Borlinghaus, P., Koprowski, H.: A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma 6:389-401, 1987. PMID2442094

91. Rodeck, U., Herlyn, M., Herlyn, D., Molthoff, C., Atkinson, B., Varello, M., Steplewski, Z., Koprowski, H.: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 47:3692-3696, 1987. PMID3297307

92. Thurin, J., Thurin, M., Kimoto, Y., Herlyn, M., Lubeck, M.D., Elder, D.E., Smereczynska, M., Karlsson, K.A., Clark, W.M., Jr., Steplewski, Z., Koprowski, H.: Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 47:1229-1233, 1987. PMID3815333

93. Tsujisaki, M., Igarashi, M., Sakaguchi, K., Eisinger, M., Herlyn, M., Ferrone, S.: Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol 138:1310-1316, 1987. PMID3100635

94. Herlyn, M., Mancianti, M.L., Jambrosic, J., Bolen, J.B., Koprowski, H.: Regulatory factors that determine growth and phenotype of normal human melanocytes. Exp Cell Res 179:322-331, 1988. PMID2461309

95. Linnenbach, A.J., Huebner, K., Reddy, E.P., Herlyn, M., Parmiter, A.H., Nowell, P.C., Koprowski, H.: Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A 85:74-78, 1988. PMID2829178

96. Mancianti, M.L., Herlyn, M., Weil, D., Jambrosic, J., Rodeck, U., Becker, D., Diamond, L., Clark, W.H., Koprowski, H.: Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol 90:134-141, 1988. PMID2828480

97. Rakowicz-Szulczynska, E.M., Herlyn, M., Koprowski, H.: Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res 48:7200-7206, 1988. PMID2461254

98. Williams, N.W., Rodeck, U., Daly, J.M., Herlyn, M.: Growth regulatory factors for human colorectal carcinoma cells in vitro. Surgical Forum 39:445-447, 1988.

99. Becker, D., Meier, C.B., Herlyn, M.: Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J 8:3685-3691, 1989. PMID2684645

100. Berd, D., Herlyn, M., Koprowski, H., Mastrangelo, M.J.: Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res 49:6840-6844, 1989. PMID2582430

101. Elder, D.E., Rodeck, U., Thurin, J., Cardillo, F., Clark, W.H., Stewart, R., Herlyn, M.: Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 49:5091-5096, 1989. PMID2548711

102. Iliopoulos, D., Ernst, C., Steplewski, Z., Jambrosic, J.A., Rodeck, U., Herlyn, M., Clark, W.H., Jr., Koprowski, H., Herlyn, D.: Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 81:440-444, 1989. PMID2918552

103. Jambrosic, J., Mancianti, M.L., Ricciardi, R., Sela, B.A., Koprowski, H., Herlyn, M.: Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus. Int J Cancer 44:1117-1123, 1989. PMID2558080

104. Kraemer, K.H., Herlyn, M., Yuspa, S.H., Clark, W.H., Jr., Townsend, G.K., Neises, G.R., Hearing, V.J.: Reduced DNA repair in cultured melanocytes and nevus cells from a patient with xeroderma pigmentosum. Arch Dermatol 125:263-268, 1989. PMID2913963


15

105. Strom, B.L., Iliopoulos, D., Atkinson, B., Herlyn, M., West, S.L., Maislin, G., Saul, S., Varello, M.A., Rodriguez-Martinez, H.A., Rios-Dalenz, J.: Pathophysiology of tumor progression in human gallbladder: flow cytometry, CEA, and CA 19-9 levels in bile and serum in different stages of gallbladder disease. J Natl Cancer Inst 81:1575-1580, 1989. PMID2795683

106. Wolf, B.C., Salem, R.R., Sears, H.F., Horst, D.A., Lavin, P.T., Herlyn, M., Itzkowitz, S.H., Schlom, J., Steele, G.D., Jr.: The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution. Am J Pathol 135:111-119, 1989. PMID2476033

107. Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A.: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50:6757-6764, 1990. PMID2208139

108. Becker, D., Beebe, S.J., Herlyn, M.: Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas. Oncogene 5:1133-1139, 1990. PMID2392322

109. Dion, A.S., Williams, C.J., Herlyn, M., Major, P.: Human milk fat globule membrane glycoproteins express blood group-related determinants primarily on mucin-like epithelial membrane antigens and gp70. Biochem Int 22:295-302, 1990. PMID1708665

110. Howe, C.C., Kath, R., Mancianti, M.L., Herlyn, M., Mueller, S., Cristofalo, V.: Expression and structure of human SPARC transcripts: SPARC mRNA is expressed by human cells involved in extracellular matrix production and some of these cells show an unusual expression pattern. Exp Cell Res 188:185-191, 1990. PMID2335186

111. Kath, R., Rodeck, U., Parmiter, A., Jambrosic, J., Herlyn, M.: Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediate lesions. Cancer Therapy and Control 1:179-191, 1990.

112. Mancianti, M.L., Clark, W.H., Hayes, F.A., Herlyn, M.: Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol 136:817-829, 1990. PMID2327470

113. Manni, A., Wright, C., Badger, B., Bartholomew, M., Herlyn, M., Mendelsohn, J., Masui, H., Demers, L.: Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. Breast Cancer Res Treat 15:73-83, 1990. PMID2322651

114. Rodeck, U., Williams, N., Murthy, U., Herlyn, M.: Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem 44:69-79, 1990. PMID2250044

115. Singletary, S.E., Williams, N.N., Rodeck, U., Larry, L., Tucker, S., Spitzer, G., Herlyn, M.: Transforming growth factor-alpha secretion by epidermal growth factor-dependent human tumor cell lines. Anticancer Res 10:1501-1505, 1990. PMID2285223

116. Strom, B.L., Maislin, G., West, S.L., Atkinson, B., Herlyn, M., Saul, S., Rodriguez-Martinez, H.A., Rios-Dalenz, J., Iliopoulos, D., Soloway, R.D.: Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer 45:821-824, 1990. PMID2335386

117. Valyi-Nagy, I.T., Murphy, G.F., Mancianti, M.L., Whitaker, D., Herlyn, M.: Phenotypes and interactions of human melanocytes and keratinocytes in an epidermal reconstruction model. Lab Invest 62:314-324, 1990. PMID2179623

118. Bröcker, E.B., Magiera, H., Herlyn, M.: Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol 96:662-665, 1991. PMID1850772

119. Cornil, I., Theodorescu, D., Man, S., Herlyn, M., Jambrosic, J., Kerbel, R.S.: Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A 88:6028-6032, 1991. PMID2068080

120. Herlyn, M., Graeven, U., Speicher, D., Sela, B.A., Bennicelli, J.L., Kath, R., Guerry, D.t.: Characterization of tenascin secreted by human melanoma cells. Cancer Res 51:4853-4858, 1991. PMID1716515


16

121. Kath, R., Jambrosic, J.A., Holland, L., Rodeck, U., Herlyn, M.: Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res 51:2205-2211, 1991. PMID2009539

122. Radrizzani, M., Benedetti, B., Castelli, C., Longo, A., Ferrara, G.B., Herlyn, M., Parmiani, G., Fossati, G.: Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions. Int J Cancer 49:823-830, 1991. PMID1835714

123. Rodeck, U., Melber, K., Kath, R., Menssen, H.D., Varello, M., Atkinson, B., Herlyn, M.: Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 97:20-26, 1991. PMID2056188

124. Becker, D., Lee, P.L., Rodeck, U., Herlyn, M.: Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 7:2303-2313, 1992. PMID1437152

125. Ura, Y., Dion, A.S., Williams, C.J., Olsen, B.D., Redfield, E.S., Ishida, M., Herlyn, M., Major, P.P.: Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues. Int J Cancer 50:57-63, 1992. PMID1728614

126. Williams, N.N., Györfi, T., Iliopoulos, D., Herlyn, D., Greenstein, D., Linnenbach, A.J., Daly, J.M., Jensen, P., Rodeck, U., Herlyn, M.: Growth-factor-independence and invasive properties of colorectal carcinoma cells. Int J Cancer 50:274-280, 1992. PMID1730521

127. Anichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M., Parmiani, G.: Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177:989-998, 1993. PMID8459226

128. Easty, D.J., Ganz, S.E., Farr, C.J., Lai, C., Herlyn, M., Bennett, D.C.: Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol 101:679-684, 1993. PMID8228328

129. Forsberg, K., Valyi-Nagy, I., Heldin, C.H., Herlyn, M., Westermark, B.: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A 90:393-397, 1993. PMID8380638

130. Iliopoulos, D., Atkinson, B., Saul, S.H., Herlyn, M., Rodriguez-Martinez, H.A., West, S.L., Maislin, G., Soloway, R.D., Strom, B.L.: Differences in antigen expression between neoplastic and nonneoplastic gallbladder epithelium. An immunohistochemical study. Dig Dis Sci 38:155-160, 1993. PMID8420749

131. Juhasz, I., Lazarus, G.S., Murphy, G.F., Shih, I.M., Herlyn, M.: Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients. J Clin Invest 92:2401-2407, 1993. PMID8227357

132. Juhasz, I., Murphy, G.F., Yan, H.C., Herlyn, M., Albelda, S.M.: Regulation of extracellular matrix proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound healing in vivo. Am J Pathol 143:1458-1469, 1993. PMID7694470

133. Juhasz, I., Albelda, S.M., Elder, D.E., Murphy, G.F., Adachi, K., Herlyn, D., Valyi-Nagy, I.T., Herlyn, M.: Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143:528-537, 1993. PMID8342600

134. Lazzaro, B., Elder, D.E., Rebers, A., Power, L., Herlyn, M., Menrad, A., Johnson, B.: Immunophenotyping of compound and spitz nevi and vertical growth-phase melanomas using a panel of monoclonal antibodies reactive in paraffin sections. J Invest Dermatol 100:313S-317S, 1993. PMID8440911

135. Mancianti, M.L., Györfi, T., Shih, I.M., Valyi-Nagy, I., Levengood, G., Menssen, H.D., Halpern, A.C., Elder, D.E., Herlyn, M.: Growth regulation of cultured human nevus cells. J Invest Dermatol 100:281S-287S, 1993. PMID8440904

136. Menrad, A., Speicher, D., Wacker, J., Herlyn, M.: Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53:1450-1455, 1993. PMID8095183


17

137. Salem, R.R., Wolf, B.C., Sears, H.F., Lavin, P.T., Ravikumar, T.S., DeCoste, D., D’Emilia, J.C., Herlyn, M., Schlom, J., Gottlieb, L.S., Steele, D.G.: Expression of colorectal carcinoma-associated antigens in colonic polyps. J Surg Res 55:249-255, 1993. PMID8412106

138. Sensi, M., Salvi, S., Castelli, C., Maccalli, C., Mazzocchi, A., Mortarini, R., Nicolini, G., Herlyn, M., Parmiani, G., Anichini, A.: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 178:1231-1246, 1993. PMID8376931

139. Valyi-Nagy, I.T., Hirka, G., Jensen, P.J., Shih, I.M., Juhasz, I., Herlyn, M.: Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest 69:152-159, 1993. PMID8350597

140. Valyi-Nagy, I., Shih, I.M., Györfi, T., Greenstein, D., Juhasz, I., Elder, D.E., Herlyn, M.: Spontaneous and induced differentiation of human melanoma cells. Int J Cancer 54:159-165, 1993. PMID8478142

141. Weiss, J., Schwechheimer, K., Cavenee, W.K., Herlyn, M., Arden, K.C.: Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 54:693-699, 1993. PMID8514460

142. Yan, H.C., Juhasz, I., Pilewski, J., Murphy, G.F., Herlyn, M., Albelda, S.M.: Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin Invest 91:986-996, 1993. PMID7680673

143. Gratas, C., Herlyn, M., Becker, D.: Isolation and analysis of novel human melanocyte-specific cDNA clones. DNA Cell Biol 13:515-519, 1994. PMID8024694

144. Hijiya, N., Zhang, J., Ratajczak, M.Z., Kant, J.A., DeRiel, K., Herlyn, M., Zon, G., Gewirtz, A.M.: Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A 91:4499-4503, 1994. PMID8183937

145. Marincola, F.M., Shamamian, P., Alexander, R.B., Gnarra, J.R., Turetskaya, R.L., Nedospasov, S.A., Simonis, T.B., Taubenberger, J.K., Yannelli, J., Mixon, A., Restifo, N.P., Herlyn, M., Rosenberg, S.A.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153:1225-1237, 1994. PMID8027550

146. Mattei, S., Colombo, M.P., Melani, C., Silvani, A., Parmiani, G., Herlyn, M.: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853-857, 1994. PMID7509778

147. Quong, R.Y., Bickford, S.T., Ing, Y.L., Terman, B., Herlyn, M., Lassam, N.J.: Protein kinases in normal and transformed melanocytes. Melanoma Res 4:313-319, 1994. PMID7858416

148. Shih, I.M., Elder, D.E., Hsu, M.Y., Herlyn, M.: Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 145:837-845, 1994. PMID7943174

149. Shih, I.M., Elder, D.E., Speicher, D., Johnson, J.P., Herlyn, M.: Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54:2514-2520, 1994. PMID8162602

150. Weber, J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J., Rosenberg, S.A.: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res 54:1766-1771, 1994. PMID7511051

151. Easty, D.J., Guthrie, B.A., Maung, K., Farr, C.J., Lindberg, R.A., Toso, R.J., Herlyn, M., Bennett, D.C.: Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 55:2528-2532, 1995. PMID7780963

152. Easty, D.J., Herlyn, M., Bennett, D.C.: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60:129-136, 1995. PMID7814145

153. Jiang, H., Lin, J., Su, Z.Z., Herlyn, M., Kerbel, R.S., Weissman, B.E., Welch, D.R., Fisher, P.B.: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10:1855-1864, 1995. PMID7753561


18

154. Mortarini, R., Gismondi, A., Maggioni, A., Santoni, A., Herlyn, M., Anichini, A.: Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res 55:4702-4710, 1995. PMID7553652

155. Soballe, P.W., Maloy, W.L., Myrga, M.L., Jacob, L.S., Herlyn, M.: Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer 60:280-284, 1995. PMID7829229

156. Hsu, M.Y., Wheelock, M.J., Johnson, K.R., Herlyn, M.: Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1:188-194, 1996. PMID9627715

157. Juhasz, I., Simon, M., Jr., Herlyn, M., Hunyadi, J.: Repopulation of Langerhans cells during wound healing in an experimental human skin/SCID mouse model. Immunol Lett 52:125-128, 1996. PMID8905406

158. Marincola, F.M., Hijazi, Y.M., Fetsch, P., Salgaller, M.L., Rivoltini, L., Cormier, J., Simonis, T.B., Duray, P.H., Herlyn, M., Kawakami, Y., Rosenberg, S.A.: Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 19:192-205, 1996. PMID8811494

159. Simon, M., Jr., Juhasz, I., Herlyn, M., Hunyadi, J.: Thrombospondin receptor (CD36) expression of human keratinocytes during wound healing in a SCID mouse/human skin repair model. J Dermatol 23:305-309, 1996. PMID9675818

160. Soballe, P.W., Montone, K.T., Satyamoorthy, K., Nesbit, M., Herlyn, M.: Carcinogenesis in human skin grafted to SCID mice. Cancer Res 56:757-764, 1996. PMID8631010

161. Andalib, A.R., Lawry, J., Ali, S.A., Murray, A.K., Sisley, K., Silcocks, P., Herlyn, M., Rees, R.C.: Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res 7:32-42, 1997. PMID9067963

162. Atillasoy, E.S., Elenitsas, R., Sauter, E.R., Soballe, P.W., Herlyn, M.: UVB induction of epithelial tumors in human skin using a RAG-1 mouse xenograft model. J Invest Dermatol 109:704-709, 1997. PMID9406808

163. Satyamoorthy, K., DeJesus, E., Linnenbach, A.J., Kraj, B., Kornreich, D.L., Rendle, S., Elder, D.E., Herlyn, M.: Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7 Suppl 2:S35-42, 1997. PMID9578514

164. Satyamoorthy, K., Soballe, P.W., Soans, F., Herlyn, M.: Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Cancer Res 57:1873-1876, 1997. PMID9157978

165. Shih, I.M., Speicher, D., Hsu, M.Y., Levine, E., Herlyn, M.: Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 57:3835-3840, 1997. PMID9288796

166. Shih, L.M., Hsu, M.Y., Palazzo, J.P., Herlyn, M.: The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 151:745-751, 1997. PMID9284823

167. Wechsler-Reya, R., Elliott, K., Herlyn, M., Prendergast, G.C.: The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res 57:3258-3263, 1997. PMID9242458

168. Atillasoy, E.S., Seykora, J.T., Soballe, P.W., Elenitsas, R., Nesbit, M., Elder, D.E., Montone, K.T., Sauter, E., Herlyn, M.: UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 152:1179-1186, 1998. PMID9588887

169. Cass, D.L., Bullard, K.M., Sylvester, K.G., Yang, E.Y., Sheppard, D., Herlyn, M., Adzick, N.S.: Epidermal integrin expression is upregulated rapidly in human fetal wound repair. J Pediatr Surg 33:312-316, 1998. PMID9498408

170. Hsu, M.Y., Shih, D.T., Meier, F.E., Van Belle, P., Hsu, J.Y., Elder, D.E., Buck, C.A., Herlyn, M.: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 153:1435-1442, 1998. PMID9811334

171. Maul, G.G., Jensen, D.E., Ishov, A.M., Herlyn, M., Rauscher, F.J., 3rd. Nuclear redistribution of BRCA1 during viral infection. Cell Growth Differ 9:743-755, 1998. PMID9751118

172. Prabhu, N.S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., El-Deiry, W.S.: p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 13:5-9, 1998. PMID9625796


19

173. Rauscher, F.J., 3rd, Morris, J.F., Fredericks, W.J., Lopez-Guisa, J., Balakrishnan, C., Jost, M., Herlyn, M., Rodeck, U.: Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms’ tumor suppressor protein. Hybridoma 17:191-198, 1998. PMID9627060

174. Ronai, Z., Yang, Y.M., Fuchs, S.Y., Adler, V., Sardana, M., Herlyn, M.: ATF2 confers radiation resistance to human melanoma cells. Oncogene 16:523-531, 1998. PMID9484842

175. Sauter, E.R., Klein-Szanto, A.J., Atillasoy, E., Montone, K.T., Goodrow, T., Binder, R.L., Seykora, J.T., Herlyn, M.: Ultraviolet B-induced squamous epithelial and melanocytic cell changes in a xenograft model of cancer development in human skin. Mol Carcinog 23:168-174, 1998. PMID9833777

176. Shih, I.M., Nesbit, M., Herlyn, M., Kurman, R.J.: A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 11:1098-1106, 1998. PMID9831208

177. Easty, D.J., Hill, S.P., Hsu, M.Y., Fallowfield, M.E., Florenes, V.A., Herlyn, M., Bennett, D.C.: Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84:494-501, 1999. PMID10502726

178. Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., Prendergast, G.C.: Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A 96:9689-9694, 1999. PMID10449755

179. Hsu, J.Y., Hsu, M.Y., Sorger, T., Herlyn, M., Levine, E.M.: Heparin/endothelial cell growth supplement regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulation of interleukin-1. In Vitro Cell Dev Biol Anim 35:647-654, 1999. PMID10614876

180. Krasilnikov, M., Adler, V., Fuchs, S.Y., Dong, Z., Haimovitz-Friedman, A., Herlyn, M., Ronai, Z.: Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 24:64-69, 1999. PMID10029412

181. Liechty, K.W., Nesbit, M., Herlyn, M., Radu, A., Adzick, N.S., Crombleholme, T.M.: Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol 113:375-383, 1999. PMID10469337

182. Mitra, J., Dai, C.Y., Somasundaram, K., El-Deiry, W.S., Satyamoorthy, K., Herlyn, M., Enders, G.H.: Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 19:3916-3928, 1999. PMID10207115

183. Moretti, S., Pinzi, C., Spallanzani, A., Berti, E., Chiarugi, A., Mazzoli, S., Fabiani, M., Vallecchi, C., Herlyn, M.: Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 84:160-168, 1999. PMID10096249

184. Nesbit, M., Nesbit, H.K., Bennett, J., Andl, T., Hsu, M.Y., Dejesus, E., McBrian, M., Gupta, A.R., Eck, S.L., Herlyn, M.: Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 18:6469-6476, 1999. PMID10597249

185. Prabhu, N.S., Somasundaram, K., Tian, H., Enders, G.H., Satyamoorthy, K., Herlyn, M., El-Deiry, W.S.: The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int J Oncol 15:209-216, 1999. PMID10402229

186. Sauter, E.R., Nesbit, M., Litwin, S., Klein-Szanto, A.J., Cheffetz, S., Herlyn, M.: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59:4876-4881, 1999. PMID10519399

187. Sauter, E.R., Nesbit, M., Watson, J.C., Klein-Szanto, A., Litwin, S., Herlyn, M.: Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 5:775-782, 1999. PMID10213212

188. Van Belle, P.A., Elenitsas, R., Satyamoorthy, K., Wolfe, J.T., Guerry, D.t., Schuchter, L., Van Belle, T.J., Albelda, S., Tahin, P., Herlyn, M., Elder, D.E.: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30:562-567, 1999. PMID10333228

189. Ayyanathan, K., Fredericks, W.J., Berking, C., Herlyn, M., Balakrishnan, C., Gunther, E., Rauscher, F.J., 3rd. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 60:5803-5814, 2000. PMID11059777


20

190. Chandler, L.A., Doukas, J., Gonzalez, A.M., Hoganson, D.K., Gu, D.L., Ma, C., Nesbit, M., Crombleholme, T.M., Herlyn, M., Sosnowski, B.A., Pierce, G.F.: FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther 2:153-160, 2000. PMID10947943

191. Fredericks, W.J., Ayyanathan, K., Herlyn, M., Friedman, J.R., Rauscher, F.J., 3rd. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell Biol 20:5019-5031, 2000. PMID10866659

192. Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Van Belle, P., Elder, D.E., Herlyn, M.: E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 156:1515-1525, 2000. PMID10793063

193. Hsu, M., Andl, T., Li, G., Meinkoth, J.L., Herlyn, M.: Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 113 ( Pt 9):1535-1542, 2000. PMID10751145

194. Margolis, D.J., Crombleholme, T., Herlyn, M.: Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 8:480-493, 2000. PMID11208175

195. Meier, F., Nesbit, M., Hsu, M.Y., Martin, B., Van Belle, P., Elder, D.E., Schaumburg-Lever, G., Garbe, C., Walz, T.M., Donatien, P., Crombleholme, T.M., Herlyn, M.: Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol 156:193-200, 2000. PMID10623667

196. Oka, M., Berking, C., Nesbit, M., Satyamoorthy, K., Schaider, H., Murphy, G., Ichihashi, M., Sauter, E., Herlyn, M.: Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 80:595-604, 2000. PMID10780675

197. Satyamoorthy, K., Oka, M., Herlyn, M.: An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res 13 Suppl 8:87-93, 2000. PMID11041363

198. Satyamoorthy, K., Chehab, N.H., Waterman, M.J., Lien, M.C., El-Deiry, W.S., Herlyn, M., Halazonetis, T.D.: Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11:467-474, 2000. PMID11007451

199. Sauter, E.R., Herlyn, M., Liu, S.C., Litwin, S., Ridge, J.A.: Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res 6:654-660, 2000. PMID10690551

200. Smedley, D., Sidhar, S., Birdsall, S., Bennett, D., Herlyn, M., Cooper, C., Shipley, J.: Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer 28:121-125, 2000. PMID10738310

201. St John, L.S., Sauter, E.R., Herlyn, M., Litwin, S., Adler-Storthz, K.: Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther 7:749-756, 2000. PMID10830722

202. Sylvester, K.G., Nesbit, M., Radu, A., Herlyn, M., Adzick, N.S., Crombleholme, T.M.: Adenoviral-mediated gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen 8:36-44, 2000. PMID10760213

203. Berking, C., Takemoto, R., Schaider, H., Showe, L., Satyamoorthy, K., Robbins, P., Herlyn, M.: Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 61:8306-8316, 2001. PMID11719464

204. Berking, C., Takemoto, R., Satyamoorthy, K., Elenitsas, R., Herlyn, M.: Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol 158:943-953, 2001. PMID11238042

205. Doukas, J., Chandler, L.A., Gonzalez, A.M., Gu, D., Hoganson, D.K., Ma, C., Nguyen, T., Printz, M.A., Nesbit, M., Herlyn, M., Crombleholme, T.M., Aukerman, S.L., Sosnowski, B.A., Pierce, G.F.: Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther 12:783-798, 2001. PMID11339895


21

206. Herlyn, M., Ferrone, S., Ronai, Z., Finerty, J., Pelroy, R., Mohla, S.: Melanoma biology and progression. Cancer Res 61:4642-4643, 2001. PMID11389102

207. Iida, J., Pei, D., Kang, T., Simpson, M.A., Herlyn, M., Furcht, L.T., McCarthy, J.B.: Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 276:18786-18794, 2001. PMID11278606

208. Li, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., Herlyn, M.: Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20:8125-8135, 2001. PMID11781826

209. Li, G., Satyamoorthy, K., Herlyn, M.: N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 61:3819-3825, 2001. PMID11325858

210. McArdle, L., Rafferty, M., Maelandsmo, G.M., Bergin, O., Farr, C.J., Dervan, P.A., O’Loughlin, S., Herlyn, M., Easty, D.J.: Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol 117:1255-1260, 2001. PMID11710941

211. Nesbit, M., Schaider, H., Berking, C., Shih, D.T., Hsu, M.Y., McBrian, M., Crombleholme, T.M., Elenitsas, R., Buck, C., Herlyn, M.: Alpha5 and alpha2 integrin gene transfers mimic the PDGF-B-induced transformed phenotype of fibroblasts in human skin. Lab Invest 81:1263-1274, 2001. PMID11555674

212. Nesbit, M., Schaider, H., Miller, T.H., Herlyn, M.: Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 166:6483-6490, 2001. PMID11359798

213. Satyamoorthy, K., Li, G., Vaidya, B., Patel, D., Herlyn, M.: Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 61:7318-7324, 2001. PMID11585772

214. Satyamoorthy, K., Muyrers, J., Meier, F., Patel, D., Herlyn, M.: Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 20:4676-4684, 2001. PMID11498790

215. Sauter, E.R., Nesbit, M., Tichansky, D., Liu, Z.J., Shirakawa, T., Palazzo, J., Herlyn, M.: Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium. Int J Cancer 92:374-381, 2001. PMID11291074

216. Sauter, E.R., Tichansky, D., Furth, E.E., Herlyn, M.: Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma. In Vitro Cell Dev Biol Anim 37:530-535, 2001. PMID11669287

217. Berking, C., Takemoto, R., Binder, R.L., Hartman, S.M., Ruiter, D.J., Gallagher, P.M., Lessin, S.R., Herlyn, M.: Photocarcinogenesis in human adult skin grafts. Carcinogenesis 23:181-187, 2002. PMID11756239

218. Brose, M.S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J.A., Albelda, S.M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P.A., Wooster, R., Stratton, M.R., Weber, B.L.: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002. PMID12460918

219. Samadi, D.S., Jacobs, I.N., Walsh, D., Bouchard, S., Herlyn, M., Crombleholme, T.M.: Adenovirus-mediated ex vivo gene transfer of human vascular endothelial growth factor in a rabbit laryngotracheal reconstruction model. Ann Otol Rhinol Laryngol 111:295-301, 2002. PMID11991579

220. Satyamoorthy, K., Li, G., Van Belle, P.A., Elder, D.E., Herlyn, M.: A versatile method for the removal of melanin from ribonucleic acids in melanocytic cells. Melanoma Res 12:449-452, 2002. PMID12394186

221. Satyamoorthy, K., Li, G., Vaidya, B., Kalabis, J., Herlyn, M.: Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ 13:87-93, 2002. PMID11864912

222. Sauter, E.R., Takemoto, R., Litwin, S., Herlyn, M.: p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 9:807-812, 2002. PMID12224020


22

223. Sauter, E.R., Yeo, U.C., von Stemm, A., Zhu, W., Litwin, S., Tichansky, D.S., Pistritto, G., Nesbit, M., Pinkel, D., Herlyn, M., Bastian, B.C.: Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62:3200-3206, 2002. PMID12036934

224. Shih, I.M., Hsu, M.Y., Oldt, R.J., 3rd, Herlyn, M., Gearhart, J.D., Kurman, R.J.: The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta 23:706-715, 2002. PMID12398810

225. Sturm, R.A., Satyamoorthy, K., Meier, F., Gardiner, B.B., Smit, D.J., Vaidya, B., Herlyn, M.: Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 62:226-232, 2002. PMID11782382

226. Velazquez, O.C., Snyder, R., Liu, Z.J., Fairman, R.M., Herlyn, M.: Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. Faseb J 16:1316-1318, 2002. PMID12060671

227. Wang, E., Miller, L.D., Ohnmacht, G.A., Mocellin, S., Perez-Diez, A., Petersen, D., Zhao, Y., Simon, R., Powell, J.I., Asaki, E., Alexander, H.R., Duray, P.H., Herlyn, M., Restifo, N.P., Liu, E.T., Rosenberg, S.A., Marincola, F.M.: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586, 2002. PMID12097256

228. Andl, C.D., Mizushima, T., Nakagawa, H., Oyama, K., Harada, H., Chruma, K., Herlyn, M., Rustgi, A.K.: Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 278:1824-1830, 2003. PMID12435727

229. Cook, A.L., Donatien, P.D., Smith, A.G., Murphy, M., Jones, M.K., Herlyn, M., Bennett, D.C., Leonard, J.H., Sturm, R.A.: Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol 121:1150-1159, 2003. PMID14708619

230. Gruss, C.J., Satyamoorthy, K., Berking, C., Lininger, J., Nesbit, M., Schaider, H., Liu, Z.J., Oka, M., Hsu, M.Y., Shirakawa, T., Li, G., Bogenrieder, T., Carmeliet, P., El-Deiry, W.S., Eck, S.L., Rao, J.S., Baker, A.H., Bennet, J.T., Crombleholme, T.M., Velazquez, O., Karmacharya, J., Margolis, D.J., Wilson, J.M., Detmar, M., Skobe, M., Robbins, P.D., Buck, C., Herlyn, M.: Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol 120:683-692, 2003. PMID12648235

231. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., Tuveson, D.A.: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198-5202, 2003. PMID14500344

232. Hirst, C.J., Herlyn, M., Cattini, P.A., Kardami, E.: High levels of CUG-initiated FGF-2 expression cause chromatin compaction, decreased cardiomyocyte mitosis, and cell death. Mol Cell Biochem 246:111-116, 2003. PMID12841351

233. Kalabis, J., Patterson, M.J., Enders, G.H., Marian, B., Iozzo, R.V., Rogler, G., Gimotty, P.A., Herlyn, M.: Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. Faseb J 17:1115-1117, 2003. PMID12692084

234. Li, G., Kalabis, J., Xu, X., Meier, F., Oka, M., Bogenrieder, T., Herlyn, M.: Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 22:6891-6899, 2003. PMID14534536

235. Liu, Z.J., Snyder, R., Soma, A., Shirakawa, T., Ziober, B.L., Fairman, R.M., Herlyn, M., Velazquez, O.C.: VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. Faseb J 17:1931-1933, 2003. PMID14519669

236. Liu, Z.J., Shirakawa, T., Li, Y., Soma, A., Oka, M., Dotto, G.P., Fairman, R.M., Velazquez, O.C., Herlyn, M.: Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23:14-25, 2003. PMID12482957

237. Meier, F., Caroli, U., Satyamoorthy, K., Schittek, B., Bauer, J., Berking, C., Moller, H., Maczey, E., Rassner, G., Herlyn, M., Garbe, C.: Fibroblast growth factor-2 but not Mel-CAM and/or beta3


23

integrin promotes progression of melanocytes to melanoma. Exp Dermatol 12:296-306, 2003. PMID12823444

238. Satyamoorthy, K., Li, G., Gerrero, M.R., Brose, M.S., Volpe, P., Weber, B.L., Van Belle, P., Elder, D.E., Herlyn, M.: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-759, 2003. PMID12591721

239. Schaider, H., Oka, M., Bogenrieder, T., Nesbit, M., Satyamoorthy, K., Berking, C., Matsushima, K., Herlyn, M.: Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103:335-343, 2003. PMID12471616

240. Song, J.H., Song, D.K., Herlyn, M., Petruk, K.C., Hao, C.: Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 9:4255-4266, 2003. PMID14519653

241. Zhang, H., Satyamoorthy, K., Herlyn, M., Rosdahl, I.: All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells—a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 24:185-191, 2003. PMID12584166

242. Al Moustafa, A.E., Foulkes, W.D., Wong, A., Jallal, H., Batist, G., Yu, Q., Herlyn, M., Sicinski, P., Alaoui-Jamali, M.A.: Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 23:5252-5256, 2004. PMID15229656

243. Berking, C., Takemoto, R., Satyamoorthy, K., Shirakawa, T., Eskandarpour, M., Hansson, J., VanBelle, P.A., Elder, D.E., Herlyn, M.: Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res 64:807-811, 2004. PMID14871803

244. Edwards, R.H., Ward, M.R., Wu, H., Medina, C.A., Brose, M.S., Volpe, P., Nussen-Lee, S., Haupt, H.M., Martin, A.M., Herlyn, M., Lessin, S.R., Weber, B.L.: Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41:270-272, 2004. PMID15060100

245. Keswani, S.G., Katz, A.B., Lim, F.Y., Zoltick, P., Radu, A., Alaee, D., Herlyn, M., Crombleholme, T.M.: Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen 12:497-504, 2004. PMID15453831

246. Kim, S.H., Kim, K., Kwagh, J.G., Dicker, D.T., Herlyn, M., Rustgi, A.K., Chen, Y., El-Deiry, W.S.: Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279:40044-40052, 2004. PMID15226295

247. Kim, J.W., Wong, C.W., Goldsmith, J.D., Song, C., Fu, W., Allion, M.B., Herlyn, M., Al-Mehdi, A.B., Muschel, R.J.: Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Lett 213:203-212, 2004. PMID15327836

248. Li, G., Fukunaga, M., Herlyn, M.: Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. Exp Cell Res 297:142-151; Corrigendum 305: 436, 2005, 2004. PMID15194432

249. Margolis, D.J., Cromblehome, T., Herlyn, M., Cross, P., Weinberg, L., Filip, J., Propert, K.: Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A. Hum Gene Ther 15:1003-1019, 2004. PMID15585116

250. van Kempen, L.C., Meier, F., Egeblad, M., Kersten-Niessen, M.J., Garbe, C., Weidle, U.H., Van Muijen, G.N., Herlyn, M., Bloemers, H.P., Swart, G.W.: Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 122:1293-1301, 2004. PMID15140234

251. Yang, L., Dan, H.C., Sun, M., Liu, Q., Sun, X.M., Feldman, R.I., Hamilton, A.D., Polokoff, M., Nicosia, S.V., Herlyn, M., Sebti, S.M., Cheng, J.Q.: Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394-4399, 2004. PMID15231645

252. Balint, K., Xiao, M., Pinnix, C.C., Soma, A., Veres, I., Juhasz, I., Brown, E.J., Capobianco, A.J., Herlyn, M., Liu, Z.J.: Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115:3166-3176, 2005. PMID16239965


24

253. Fang, D., Nguyen, T.K., Leishear, K., Finko, R., Kulp, A.N., Hotz, S., Van Belle, P.A., Xu, X., Elder, D.E., Herlyn, M.: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-9337, 2005. PMID16230395

254. Gorgoulis, V.G., Vassiliou, L.V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Ditullio, R.A., Jr., Kastrinakis, N.G., Levy, B., Kletsas, D., Yoneta, A., Herlyn, M., Kittas, C., Halazonetis, T.D.: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913, 2005. PMID15829965

255. Kumar, S.M., Acs, G., Fang, D., Herlyn, M., Elder, D.E., Xu, X.: Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166:823-830, 2005. PMID15743794

256. McArdle, L., Rafferty, M.M., Satyamoorthy, K., Maelandsmo, G.M., Dervan, P.A., Herlyn, M., Easty, D.J.: Microarray analysis of phosphatase gene expression in human melanoma. Br J Dermatol 152:925-930, 2005. PMID15888148

257. Price, K.L., Herlyn, M., Dent, C.L., Gewert, D.R., Linge, C.: The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res 15:91-98, 2005. PMID15846141

258. Smalley, K.S., Brafford, P., Haass, N.K., Brandner, J.M., Brown, E., Herlyn, M.: Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166:1541-1554, 2005. PMID15855653

259. Zhang, T., Somasundaram, R., Berencsi, K., Caputo, L., Rani, P., Guerry, D., Furth, E., Rollins, B.J., Putt, M., Gimotty, P., Swoboda, R., Herlyn, M., Herlyn, D.: CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol 174: 5856-5863, 2005. PMID15843590

260. Fang, D., Leishear, K., Nguyen, T.K., Finko, R., Cai, K., Fukunaga, M., Li, L., Brafford, P.A., Kulp, A.N., Xu, X., Smalley, K.S., Herlyn, M.: Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 24:1668-1677, 2006. PMID 16574754

261. Liu, Z.J., Xiao, M., Balint, K., Soma, A., Pinnix, C.C., Capobianco, A.J., Velazquez, O.C., Herlyn, M.: Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MPAK and PI3K/Akt pathways and requires MAML1. FASEB J, 20: 1009-1011, 2006. PMID16571776

262. Liu, Z.-J., Xiao, M., Balint, K., Smalley, K.S.M., Brafford, P., Qiu, E., Pinnix, C.C., Li, X., Herlyn, M.: Notch1 signaling promotes primary melanoma progression by activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-kKnase-Akt pathways and upregulating N-cadherin expression. Cancer Res 66: 4182-4190, 2006. PMID16618740

263. Oka, M., Norose, K., Matsushima, K., Nishigori, C., Herlyn, M.: Overexpression of IL-8 in the cornea induces ulcer formation in the SCID mouse. Br J Ophthalmol. 90:612-615, 2006. PMID16418304

264. Oka, M., Nishigori, C., Kageshita, T., Hsu, M.Y., Penmatcha, S., Herlyn, M.: Expression of PKC isoforms in human melanocytic cells in situ. J Dermatol Sci 41:157-161, 2006. PMID16406501

265. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., Herlyn, M.: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molec Cancer Therapy 5: 1136-1144, 2006. PMID 16731745

266. Yu, H., Fang, D., Kumar, S.M., Li, L., Nguyen, T. K., Acs, G., Herlyn, M., Xu, X.: Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol 168:1879-1988, 2006. PMID16723703

267. Hoek, K.S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., Schadendorf, D., Dummer, R.: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pig. Cell Res. 19: 290-302, 2006. PMID16827748

268. Spoettl, T., Hausmann, M., Herlyn, M., Gunckel, M., Falk, W., Herfarth, H., Schoelmerich, J., Rogler, G.: Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. Clin. Exp. Immunol. 145: 190-199, 2006. PMID16792690

269. Spoettl, T., Hausmann, M., Gunckel, M., Herfarth, H., Herlyn, M., Schoelmerich, J., Rogler, G.: A new organotypic model to study cell interactions in the intestinal mucosa. Eur. J. Gastroenterol. Hepatol. 18: 901-909, 2006. PMID16825910


25

270. Liu, j., Kumar, S.K.G., Yu, D., Molton, S.A., McMahon, M., Herlyn, M., Thomas-Tikhonenko, A., and Fuchs, S.Y.: Oncogenic BRAF regulates ß-Trep expression and NF-ΚB activity in human melanoma cells. Oncogene 26: 1954-1958, 2007. PMID 170001349

271. Dicker, D.T., Lerner, J., van Belle, P., Barth, S.F., Guerry, D. 4th, Herlyn, M., Elder D.E., and El-Deiry, W.S.: Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol. Ther. 5: 1033-1038, 2006. PMID 16931902

272. Andl, C.D., Fargnoli, B.B. Okawa, T., Bowser, M., Takaoka, M., Nakagawa, H., Klein-Szanto, A., Hua, X., Herlyn, M., and Rustgi, A.K.: Coordinated functions of E-cadherin and TGFß receptor II in vitro and in vivo. Cancer Res., 66: 9878-9885, 2006. PMID 17047049

273. Fukunaga-Kalabis, M., Martinez, G., Liu, Z-J., Kalabis, J., Mrass, P., Weninger, W., Firth, S.M., Planque, N., Perbal, B., Herlyn, M.: CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol. 175: 563-569, 2006. PMID 17101694

274. Oyama, K., Okawa, T., Nakagawa, H., Takaoka, M., Andl, C.C., Kim, S-H, Klein-Szanto, A., Diehl, J.A., Herlyn, M., El-Deiry, W., Rustgi, A.K.: Akt induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene 26: 2353-2364, 2006. PMID 17043653

275. King, A.J., Patrick, D.R., Batorsky, R.S., Ho, M.L., Do, H.T., Zhang, S-Y., Kumar, R., Rusnak, D.W., Takle, A.K., Wilson, D.M., Hugger, E., Wang, L., Karreth, F., Lougheed, J.C., Lee, J., Chau, D., Stout, T.J., May, E.W., Rominger, C.M., Schaber, M.D., Luo, L., Lakdawala, A.S., Adams, J.L., Contractor, R.G., Smalley, K.A.M., Herlyn, M., Morrissey, M.M., Tuveson, D.A., Huang, P.S.: Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66: 11100-11105, 2006. PMID 17145850

276. Smalley, K.S.M., Contractor, R., Haass, N.K., Kulp, A. N., Atilla-Gokcumen, G.E., Williams, D.S., Bregman, H., Flaherty, K.T., Soengas, M.S., Meggers, E., Herlyn, M.: A organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67: 209-217, 2007. PMID 17210701

277. Lioni, M., Brafford, P., Andl, A., Rustgi, A., El-Deiry, W., Herlyn, M., Smalley, K.S.M.: Dysregulation of Claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am. J. Pathol. 170: 709-721, 2007. PMID 17255337

278. Smalley, K.S., Contractor, R., Haass, N.K., Lee, J.T., Nathanson, K.L., Medina, C.A., Flaherty, K.T., Herlyn, M.: Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Brit. J. Cancer 96: 445-449, 2007. PMID 17210701

279. Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., Maczey, E., Herlyn, M., and Schitteck, B.: Combining targeting MAPK and AKT signaling pathways is a promising strategy for melanoma therapy. Br J Derm 156: 1204-1213, 2007. PMID 17388918

280. Kumar, S.M., Yu, H., Edwards, R., Chen, L., Kazianis, S., Brafford, P., Acs, G., Herlyn, M., Xu, X.: Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 67: 3177-3184, 2007. PMID 17409425

281. Thomas, R.K., Baker, A.C., Debiasi, R.M., Winckler, W., Laframboise, T., Lin, W.M., Wang, M., Feng, W., Zander, T., Macconnaill, L.E., Lee, J.C., Nicoletti, R., Hatton, C., Goyette. M., Girard, L., Majmudar, K., Ziaugra, L., Wong, K.K., Gabriel, S., Beroukhim, R., Peyton, M., Barretina, J., Dutt, A., Emery, C., Greulich, H., Shah, K., Sasaki, H., Gazdar, A., Minna, J., Armstrong, S.A., Mellinghoff, I.K., Hodi, F.S., Dranoff, G., Mischel, P.S., Cloughesy, T.F., Nelson, S.F., Liau, L.M., Mertz, K., Rubin, M.A., Moch, H., Loda, M., Catalona, W., Fletcher, J., Signoretti, S., Kaye, F., Anderson, K.C., Demetri, G.D., Dummer, R., Wagner, S., Herlyn, M., Sellers, W.R., Meyerson, M., Garraway, L.,A.: High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39: 347-351, 2007 PMID 17293865. Corrigendum: 39: 567, 2007. PMID 17392811

282. Seidl, H., Richtig, E., Tilz, H., Stefan, M., Schmidbauer, U., Asslaber, M., Zatloukal, K., Herlyn, M., Schaider, H.: Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol. 38: 768-780, 2007. PMID 17306330

283. Lopez-Bergami, P., Huang, C., Goydos, J.S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K.S., Mahale, A., Eroshkin, A., Aaronson, S., Ronai, Z.: Re-wired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460, 2007. PMID 17482134


26

284. Spittle, C., Ward, M.R., Nathanson, K.L., Gimotty, P.A., Rappaport, E., Brose, M.S.., Medina, A., Letrero, R., Herlyn, M., Edwards, R.H.: Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. J. Molec. Diagn. 9: 464-471, 2007. PMID17690212

285. Kumar, K.G.S., Liu, J., Yu, D., Thomas-Tikhonenko, A., Herlyn, M., Fuchs, S.Y.: Raf inhibitor stabilizes receptor for type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol. Ther. 6: 1437-1441, 2007. PMID17873516

286. Wenke, A.K., Kjellman, C., Lundgren-Akerlund, E., Uhlmann, C., Haass, N.K., Herlyn, M., Bosserhoff, A.K.: Expression of integrin alpha 10 is induced in melanoma. Cell Oncol. 29: 373-386, 2007. PMID17726260

287. Lin, W.M., Baker, A.C., Beroukhim, R., Winkler, W., Feng, W., Marmion, J., Laine, E., Greulich, H., Tseng, H., Gates, C., Hodi, F.S., Dranoff, G. M., Sellers, W. R., Thomas, R. K., Meyerson, M., Golub, T. R., Dummer, R., Herlyn, M., Getz, G., Garraway, L.A.: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68: 664-673, 2008. PMID18245465

288. Okawa, T., Michaylira, C. Z., Kalabis, J., Stairs, D. B., Nakagawa, H., Andl, C., Johnstone, C. N., Klein-Szanto, A. I., El-Deiry, W. S., Cukierman, E., Herlyn, M., Rustgi, A. K.: The functional interplay between EGFR, hTERT activation and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induce tumor development, invasion and differentiation. Genes and Development 21: 2788-2803, 2007. PMID17974918

289. Fukunaga-Kalabis, M., Martinez, G., Telson, S.M., Liu, Z.-J., Balint, K., Juhasz, I., Elder, D.E., Perbal, B., Herlyn, M.: Loss of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27: 2552-2558, 2007. PMID17968313

290. Han, M.-J., Herlyn, M., Fisher, A.B. Speicher, D. W.: Microscale solution IEF combined with 2-D DIGE substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue extracts. Electrophoresis 29: 695-705, 2008. PMID18186533

291. Haass, N.K., Sproesser, K., Nguyen, T.K., Contractor, R., Medina, C. A., Nathanson, K. L., Herlyn, M., Smalley, K. S. M.: The MEK inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 14: 230-239, 2008. PMID18172275

292. Tsai, J., Lee, J.T., Wang, W. Zhang, J., Cho, H., Mamo, S., Bremer, R., Gilette, S., Kong, J., Haass, N.K., Sproesser, K., Li, L., Smalley, K.S.M., Fong, D., Zhu, Y-L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Liu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S-H, Schlessinger, J., Zhang, K.Y.J., West, B., Powell, B., Habets, G., Zhang, C., Ibrahim, P.N. Hirth, P., Artis, D.R., Herlyn, M., Bollag, G.: Discovery of a novel selective inhibitor of oncogenic B-Raf kinase with potent anti-melanoma activity. Proc. Nat. Acad. Sc. (USA) 26: 3041-3049, 2008. PMID18287029 (PMCID2268581)

293. Zecchini, S., Bianchi, M., Colombo, N., Fasani, R., Goisis, G., Casadio, C., Viale, G., Liu, J., Herlyn, M., Godwin, A., Nuciforo, P., Cavallaro, U.: The differential role of L1 in normal and transformed ovarian surface epithelium. Cancer Res. 68: 1110-1118, 2008. PMID18281486

294. Gordon, A., Kozin, E.D., Keswani, S.G., Vaikunth, S.S., Katz, A.B., Zoltick, P.W., Favata, M., Radu, A.P., Soslowsky, L.J., Herlyn, M., Crombleholme, T.M.: Permissive environment in postnatal wounds by adenoviral-mediated overexpression of the anti-inflammatroy cytokine interleukin-10 prevents scar formation. Wound Repair Regen. 16: 70-79, 2008. PMID18086289

295. Sigalotti, L., Covre, A., Zabierowski, S., Himes, B., Colizzi, F., Natali, P.G., Herlyn, M., Maio, M.: Cancer testis antigens in human melanoma stem cells: Expression, distribution and methylation status. J Cell. Physiol. 215: 287-291, 2008. PMID1802582

296. Noma, K., Smalley, K.S.M., Lioni, M., Naomoto, Y., Tanaka, N., El-Deiry, W., King, A.J., Nakagawa, H., Herlyn, M.: An essential role for stromal fibroblasts and transformating growth factors (TGF)-ß in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 134: 1981-1993, 2008. PMID18439605 (PMCID2562524)

297. Maksimoska, J., Williams, D.S., Atilla-Gokcumen, G.E., Smalley, K.S.M., Carroll, P. J., Webster, R. D., Filippakopoulos, P., Knapp, S., Herlyn, M., Meggers, E.: Isostructural ruthenium and osmium complexes display highly similar bioactivities. Chemistry 14: 4816-4822, 2008. PMID18425743 (PMCID2753370)


27

298. Alfano, R.W., Leppla, S.H., Liu, S., Bugge, T.H., Herlyn, M. Smalley, K.S., Duesberg, N.S., Houghton, A., Frankel, A.E.: Cytotoxicity of the engineered matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molec. Cancer Therap. 8: 1218-1226, 2008. PMID18483309 (PMCID2757055)

299. Kalabis, J., Li, G., Fukunaga-Kalabis, M., Rustgi, A., Herlyn, M: Endothelin-3 stimulates survival of goblet cells in organotypic cultures of human colonic epithelium. Am. J Physiol - GI Liver Physiol., 295: G1182-1189, 2008 PMID18832450 (PMCID2604801)

300. Smalley, K.S.M., Contractor, R., Nguyen, T.K., Xiao, M., Medinca, A., Edwards, R., Muthusamy, V., King, A.J., Flaherty, K.T., Bosenberg, M., Herlyn, M., Nathanson, K.L.: Identification of a novel sub-group of melanomas with kit/cyclin-dependent kinase-4 overexpression. Cancer Res. 68: 5743-5752, 2008. PMID18632627 (PMCID2615688)

301. Xie, P., Williams, D.S., Atilla Gokumen, G.E., Milk, L., Xiao, M., Smalley, K.S., Herlyn, M., Meggers, E., Marmorstein, R.: Structure-based design of an organoruthenium phosphotidyl-inositol-3-kinase inhibitor revieals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 3: 305-316, 2008. PMID18484710 (NIHMS 53988)

302. Smalley, K.S.M., Lioni, M., Palma, M.D., Xiao, M., Desai, B., Eghazi, S., Hansson, J., W, H., King, A.J., Flaherty, K.T., Herlyn, M., Nathanson, K.L.: Cyclin D1 mediates BRAF inhibitor resistance in a sub-set of BRAF-V600E mutated melanomas. Molec. Can. Ther: 7: 2876-2883, 2008. PMID18790768 (PMCID2651569)

303. Lioni, M., Noma, K, Snyder, A., Rustgi, A., Diehl, J.A. , Herlyn, M., Smalley, K.: Bortezomib-induced cellular stress via the p38 MAPK pathway leads to a DNA damage response and apoptosis in esophageal squamous cell carcinoma cells. Molec. Cancer Ther: 7: 2866-2875, 2008. PMID18790767

304. Harada, H., Nakagawa, H., Takaoka, M., Lee, J., Herlyn, J., Diehl, J.A., Rustgi, A.K.: Cleavage of MCM2 licensing proteins fosters senescence in human keratinocytes. Cell Cycle 7: 3534-3538, 2008. PMID19001876 (PMCID2736109)

305. Kalabis, J., Oyama, K., Okawa, T., Nakagawa, H., Michaylira, C.Z., Stairs, D.B., Figueiredo, J.L., Mahmood, U., Diehl, J.A., Herlyn, M., Rustgi, A.K.: A sub-population of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J. Clin. Invest. 118: 3860-3869, 2008. PMID19005570 (PMCID2579884)

306. Smalley, K.S.M., Xiao, M., Villanueva, J., Nguyen, T.K., Flaherty, K.T., Letrero, R., Nathanson, K.L., Herlyn, M.: CRAF inhibition induces Bcl-2 dependent apoptosis in melanomas with non V600E BRAF mutations. Oncogene 28: 85-94, 2009. PMID18794803

307. Greshok, J., Nathanson K., Medina, A., Ward, M.R., Herlyn, M., Weber, B.L., Zaks, T.Z.: Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma derived cell lines. Genes, Chromosomes and Cancer, 48: 419-428 2009. PMID19226609 (PMC2885833)

308. Yu, H., McDaid, R., Lee, J., Possik, P., Kumar, S.M., Elder, D.E., van Belle, P., Gimotty, P., Guerra, M., Hammond, R., Nathanson, K.L., Dalla Plama, M., Herlyn, M, Xu, X.: Role of BRAF mutation and p53 inactivation during transformation of a sub-population of primary human melanocytes. Am. J. Pathol. 174: 2367-2377, 2009. PMID19389934 (PMCID2684200)

309. Pinnix, C. C., Lee, J.T., Liu, Z-J. McDaid, R., Balint, K., Beverly, L.J., Brafford, P.A., Xiao, M., Himes, B., Zabierowski, S.E., Yashiro-Ohtani, Y., Nathanson, K.L., Bengston, A., Pollock, P.M., Weeraratna, A.T., Nickoloff, B.J., Pear, W.E., Capobianco, A.J., Herlyn, M.: Active Notch1 protein confers a transformed phenotype to primary human melanocytes. Cancer Res. 69: 5312-5320, 2009. PMID19549918 (PMC2755513))

310. Degenhardt, Y., Huang, J., Horiates, G., Nathanson, K., Yang, X., Herlyn, M., Weber, B.: Distinct MHC gene expression patterns during progression of melanoma. Genes, Chromosomes, Cancer: 49:144-154, 2010. PMID19907984 (PMC2796267)

311. Katz, A.B., Keswani, S. G., Habli, M., Lim, F.Y., Zoltick, P.W., Midrio, P., Kozin, E.D., Herlyn, M., Crombleholme, T.M.: Placental gene transfer: Transgene screening in mice for trophic effects on the placenta. Am. J. Obstet. Gynocol. 201: 499.e1-8, 2009. PMID19716119. (PMC2885953)


28

312. Li, L., Fulunaga-Kalabis, M., Yu, H., Xu, X., Kong, J., Lee, J.T. Herlyn, M.: Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci 123: 853-860, 2010. PMID20159965 (PMC2831759)

313. Ohashi, S., Natsuizaka, M., Wong, G.S., Michaylira, C.Z., Grugan, K.D., Nakagawa, N., Klein-Szanto, A.J., Herlyn,M., Diehl, J.A., Rustgi, A.K., Nakagawa, H.: EGFR and mutant p53 expand esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res. 70: 4174-4184, 2010. PMID20424117

314. Basu, D., Nguyen, T-T., Montone, K.T., Zhang, G., Wang, L-P., Diehl, J.A., Rustgi, A. K. Lee, J.T., Weinstein, G.S., Herlyn, M.: Mesenchymal sub-populations within squamous cell carcinomas exhibiting chemoresistance and phenotypic plasticity. Oncogene 29: 4170-4182, 2010. PMID20498638

315. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford, P.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., Herlyn, M.: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594, 2010. PMID204782552 (PMC2882693).

316. Natsuizaka, M., Ohashi, S., Wong, G., Ahmadi, A., Kalman, R., Budo, D., Klein-Szanto, A., Herlyn, M., Diehl, A., Nakagawa, H.: Insulin-like growth factor binding protein-3 promotes transforming growth factor-ß1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis 31: 1344-1353, 2010. PMID20513670 (PMC2915630)

317. Michaylira, C.Z., Wong, G.S., Miller, C.G., Gutierrez, C.M. Nakagawa, H., Hammond, R., Klein-Szanto, A.J., Lee, J.S., Kim, S.B., Herlyn, M., Diehl, J.A., Gimotty, P., Rustgi, A.K.: Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res. 70: 5281-5291, 2010. PMID20516120

318. Grugan, K.D., Miller, C.G., Yao, Y., Michaylira, C.Z., Ohashi, S., Klein-Szanto, A.J., Diehl, J.A., Herlyn, M., Han, M., Nakagawa, H., Rustgi, A.K.: Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal cell carcinoma invasion. Proc. Natl. Acad. Sci (USA) 107: 11026-11031, 2010. PMID20534479 (PMC2890722)

319. Ohashi, S., Natsuizaka, M., Yashiro-Ohtani, Y., Kalman, R. A., Nakagawa, M., Wu, L., Klein-Szanto, A.J., Herlyn, M., Diehl, J.A., Kathz, J.P., Pear, W.S., Seykora, J.T., Nakagawa, H.: NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology: 139: 2113-,2123, 2010. PMID 20801121

320. Fukunaga-Kalabis, M., Martinez, G., Nguyen, T-T.K, Kim, D., Santiago-Walker, A., Roesch, A., Herlyn, M.: Tenascin promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 29: 6115-6124, 2010. PMID 2072997

321. Aggarwal, P., Vaites, L.P., Kim, J. K., Mellert, H., Nakagawa, H., Herlyn, M., Rustgi, A., McMahon, S.B., Diehl, J.A.: Nuclear Cyclin D1/CDK4 minase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18: 329-340, 2010. PMID 20951943 (PMC2957477)

322. Lee, J., Li, L., Brafford, P., Sproesser, K., Haass, N., Smalley, K., van den Eijnden, M., Halloran, M., Tsai, J., Bollag, G., Herlyn, M: PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibitrs V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827, 2010. PMID20973932

323. Han, M-J., Wang, H., Beer, L.A., Tang, H-Y., Herlyn, M., Speicher, D.: A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics 10: 4450-4462, 2010. PMID21082759

324. Villanueva, J, Vultur, A., Lee, J.T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A.K., Wubenhorst, B., Xu, X., Gimotty, P.A., Kee, D., Santiago-Walker, A.E., Letrero, R., D’Andrea, K., Pushparajan, A., Hayden, J.E., Dahlman, K., Laquerre, S., McArthur, G., Sosman, J., Nathanson, K.L., Herlyn, M.Acquired resistance to BRAF inhibitors mediated by an A/B/C RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010. PMID21156289. Commentaries on the paper:


29

1.Mutant BRAF melanomas--dependence and resistance. Poulikakos PI, Rosen N.Cancer Cell. 2011 Jan 18;19(1):11-5.

2. Targeting RAF: trials and tribulations. Downward J. Nat Med. 2011 Mar;17(3):286-8. 3. Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug. Tuma RS. J Natl Cancer Inst. 2011 Feb 2;103(3):170-1, 177. Epub 2011 Jan 17. 4. Parsing out the complexity of RAF inhibitor resistance. McMahon M. Pigment Cell & Melanoma Research. “Accepted Article”; doi: 10.1111/j.1755- 148X.2010.00824.x 5. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Rebecca VW, Smalley KS. Expert Opin Investig Drugs. 2011 Feb;20(2):137-40. 6. Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease. Vultur A, Villanueva J, Herlyn M. Clin Cancer Res. 2011 Apr 1;17(7):1658-63. Epub 2011. Mar 29. 7. Resistance to BRAF inhibitors: Unraveling mechanisms and future treatment options. Jessie Villanueva, Adina Vultur, and Meenhard Herlyn. Cancer Research, 2011. In press 8. Resistance to BRAF inhibitors. Villanueva J and Herlyn M. Invited review, British Journal of Cancer. 9. Highlights from Recent Cancer Literature Cancer Res 2011;71:627-628. Published online February 1, 2011. 10.Companies compete over mutation-specific melanoma drugs. Cassandra Willyard. Nature Medicine 17(3):268. March 2011. 11. Faculty of 1000. 3 EVALUATIONS: Daniel G Gioeli and Michael Weber; Randall Moon; Ashani Weeraratna. Jan 2011. 12. Abramsom Cancer Center of the University of Pennsylvania. Events Bulletin. January 18, 2011. 13. Phase III Trial Shows Increased Survival in Metastatic Melanom: Genetics will be the key to better response, longer survival, and counteracting resistance. Margot Fromer. The Asco Post. May 2011. 14. Killing Drug-Resistant Melanoma Requires Combination Therapy. Greg Lester. Eureka (Dec. 13, 2010), ScienceDaily (Dec.15, 2010)

325. Thurber, A.E., Douglas, G., Sturm, E.C., Zabierowski, S.E., Smit, D.J., Ramakrishnan, S.N., Hacker, E., Leonard, J.H., Herlyn, M., Sturm, R.A.: Inverse expression of BRN2 and MITF transcription factors in melanoma spheres and tumor xenografts regulate the NOTCH pathway. Oncogene. 2011 Febr. 28 [Epub ahead of print]. PMID21358674

326. Magnitsky, S., Roesch, A., Herlyn, M., Glickson J.D.: In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magn. Reson. Med. April 26 (epub ahead of print). 2011. PMID21523820

327. Basu, D., Montone, K.T., Wang, L-P, Gimotty, P.A., Hammond, R., Diehl, J.A., Rustgi, A.K., Lee, J.T., Rasanen, K, Weinstein, G.S., Herlyn, M.: Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle 10: 2008-20016, 2011. PMID21558812.

328. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30: 3036-3048, 2011. PMID21358674

329. Li, L., Fukunaga-Kalabis, M., Herlyn, M.: The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J. Vis. Exp. Aug 3; 54.pli 2937. doi: 10.3791/2937. http://www.jove.com/details.php?id=2937&status=a4943k. PMID 21847077

330. Han, M.J., Wang, H., Beer, L.A., Tank, H.Y., Herlyn, M., Speicher, D.: A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics Clin Appl. Augh 5 (7-8): 464, doi: 10. 1002/prca.201190040. PMID21805656

331. Zabierowski, S.E., Baubet, V., Himes, B, Li, L., Fukunaga-Kalabis, M., Patel, S., McDaid, R., Guerra, M., Gimotty, P., Dahamne, N., and Herlyn, M.: Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells, Sept. 21 (epub ahead of print), 2011. PMID21948558.

332. Ohashi, S., Natsuizaka, M., Naganuma, S., Kagawa, S., Kimura, S., Itoh, H., Kalman, R.A., Nakagawa, M., Darling, D.S., Basu, D., Gimotty, P.A., Klein-Szanto, A.J., Diehl, J.A., Herlyu, M., Nakagawa, Hi.: A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT competent cells that express the ZEB transcription factors. Cancer Res. 2011 Sep 2 [Epub ahead of print], 2011. PMID21890822


30

333. Blanck, S., Cruchter, T., Vultur, A., Riedel, R., Harms, K., Herlyn, M., Meggers, E.: Organometallic pyridylnaphtalamide complexes as protein kinase inhibitors. Organometallics 30: 4598-4606, 2011. PMID21918590.

334. Flach, E.H., Rebecca, V.W., Herlyn, M., Smalley, K.S.M., Anderson, A.R.A.: Fibroblasts contribute to melanoma tumor growth and drug resistance. Molecular Pharmaceutics, E-pub ahead of print, 2011.

Research Publications, peer-reviewed reviews:

1. Koprowski, H., Herlyn, M.: Human tumor antigens, In: Wahren, B., ed., Molecular Biology of Tumor Cells, Raven Press, New York 1985, pp. 123-138.

2. Ross, A.H., Herlyn, M., Maul, G.G., Koprowski, H., Bothwell, M., Chao, M., Pleasure, D., Sonnenfeld, K.H.: The nerve growth factor receptor in normal and transformed neural crest cells. Ann N Y Acad Sci 486:115-123, 1986. PMID3032054

3. Herlyn, M., Clark, W.H., Rodeck, U., Mancianti, M.L., Jambrosic, J., Koprowski, H.: Biology of tumor progression in human melanocytes. Lab Invest 56:461-474, 1987. PMID3553733

4. Herlyn, M., Rodeck, U., Koprowski, H.: Shedding of human tumor-associated antigens in vitro and in vivo. Adv Cancer Res 49:189-221, 1987. PMID3314394

5. Herlyn, M., Clark, W.H.J.: Human melanoma: Biology of tumor progression. The Melanoma Letter 5:3-4, 1987.

6. Rodeck, U., Menssen, H.D., Herlyn, M.: Growth factors in the pathogenesis of malignant diseases. Dtsch Med Wochenschr 113:904-906, 1988. PMID3286186

7. Herlyn, M., Koprowski, H.: Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol 6:283-308, 1988. PMID3289568

8. Rodeck, U., Herlyn, M.: Characteristics of cultured human melanocytes from different stages of tumor progression. Cancer Treat Res 43:3-16, 1988. PMID2908575

9. Kath, R., Herlyn, M.: Molecular biology of tumor antigens. Curr Opin Immunol 1:863-866, 1989. PMID2679733

10. Williams, N.N., Daly, J.M., Herlyn, M.: Primary colorectal carcinoma cell lines contain subpopulations with invasive properties. Surgical Forum 40:400-403, 1989.

11. Herlyn, M., Menrad, A., Koprowski, H.: Structure, function, and clinical significance of human tumor antigens. J Natl Cancer Inst 82:1883-1889, 1990. PMID2250310

12. Herlyn, M.: Human melanoma: development and progression. Cancer Metastasis Rev 9:101-112, 1990. PMID2253310

13. Herlyn, M., Kath, R., Williams, N., Valyi-Nagy, I., Rodeck, U.: Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv Cancer Res 54:213-234, 1990. PMID2404378

14. Valyi-Nagy, I., Herlyn, M.: Melanocyte maturation and differentiation. Lab Invest 63:276-277, 1990.

15. Herlyn, M., Malkowicz, S.B.: Regulatory pathways in tumor growth and invasion. Lab Invest 65:262-271, 1991. PMID1890806

16. Rodeck, U., Becker, D., Herlyn, M.: Basic fibroblast growth factor in human melanoma. Cancer Cells 3:308-311, 1991. PMID1931440

17. Rodeck, U., Herlyn, M.: Growth factors in melanoma. Cancer Metastasis Rev 10:89-101, 1991. PMID1873858

18. Herlyn, D., Linnenbach, A., Koprowski, H., Herlyn, M.: Epitope- and antigen-specific cancer vaccines. Int Rev Immunol 7:245-257, 1991. PMID1779173

19. Valyi-Nagy, I.T., Herlyn, M.: Regulation of growth and phenotype of normal human melanocytes in culture. Cancer Treat Res 54:85-101, 1991. PMID1673861

20. Herlyn, D., Adachi, K., Koprowski, H., Herlyn, M.: Experimental model of human melanoma metastases. Cancer Treat Res 54:105-118, 1991. PMID1673854

21. Graeven, U., Rodeck, U., Weinmann, R., Herlyn, M.: Stable transfection of human malignant melanoma cells with basic fibroblast growth factor antisense cDNA. Ann N Y Acad Sci 660:293-294, 1992. PMID1340139


31

22. Graeven, U., Herlyn, M.: In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression. J Immunother 12:199-202, 1992. PMID1445812

23. Menrad, A., Herlyn, M.: Tumor progression, biology, and host response in melanoma. Curr Opin Oncol 4:351-356, 1992. PMID1591308

24. Elder, D.E., Herlyn, M.: Antigens associated with tumor progression in melanocytic neoplasia. Pigment Cell Res Suppl 2:136-143, 1992. PMID1409415

25. Shih, I.M., Herlyn, M.: Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol 100:196S-203S, 1993. PMID8381840

26. Soballe, P.W., Herlyn, M.: Cellular pathways leading to melanoma differentiation: therapeutic implications. Melanoma Res 4:213-223, 1994. PMID7950357

27. Herlyn, M., Shih, I.M.: Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 7:81-88, 1994. PMID8066024

28. Nesbit, M., Herlyn, M.: Adhesion receptors in human melanoma progression. Invasion Metastasis 14:131-146, 1994. PMID7657508

29. Shih, I.M., Herlyn, M.: Autocrine and paracrine roles for growth factors in melanoma. In Vivo 8:113-123, 1994. PMID7519892

30. Soballe, P.W., Daly, J.M., Herlyn, M.: Human carcinogenesis in SCID/human chimeras: A cutaneous model. ACS Surgical Forum 65:559-561, 1994.

31. Herlyn, M., Satyamoorthy, K.: Activated ras. Yet another player in melanoma? Am J Pathol 149:739-744, 1996. PMID8780377

32. Satyamoorthy, K., Nesbit, M., Hsu, M.-Y., Herlyn, M.: Utility of adenoviruses as gene expression modules in melanoma. Biomedical and Health Res 12:71-77, 1996.

33. Hsu, M.-Y., Herlyn, M.: Cultivation of normal human epidermal melanocytes, In Jones, G. E., ed.,Methods in Molecular Medicine: Human Cell Culture Protocols, Humana Press, Totowa, NJ 1996, pp. 9-20.

34. Smalley, K.S.M., Herlyn, M.: Towards the targeted therapy of melanoma.. Mini-Rev. Med. Chem. 6:109-120, 2006.

35. Satyamoorthy, K., Herlyn, M.: Melanoma: Molecular and Cellular Abnormalities, In Bertino, J. R., ed.,Encyclopedia of Cancer II, Academic Press, San Diego, CA 1997, pp. 1042-1050.

36. Sauter, E.R., Herlyn, M.: Molecular biology of human melanoma development and progression. Mol Carcinog 23:132-143, 1998. PMID9833774

37. Meier, F., Satyamoorthy, K., Nesbit, M., Hsu, M.Y., Schittek, B., Garbe, C., Herlyn, M.: Molecular events in melanoma development and progression. Front Biosci 3:D1005-1010, 1998. PMID9740553

38. Kamb, A., Herlyn, M.: Malignant melanoma, In Vogelstein, B., Kinzler, K. W., Eds.,The genetic basis of human cancer, McGraw-Hill Co., New York 1998, pp. 507-518.

39. Nesbit, M., Seatluri, V., Herlyn, M.: Biology of melanocytes and melanoma, In Balch, C., Houghton, A., Sober, A. J., Soong, S., Eds.,Cutaneous melanma, Quality Med. Publ., St. Louis, MO 1998, pp. 463-473.

40. Satyamoorthy, K., Meier, F., Hsu, M.Y., Berking, C., Herlyn, M.: Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. Cancer Metastasis Rev 18:401-405, 1999. PMID10721493

41. Hsu, M.-Y., Elder, D.E., Herlyn, M.: Melanoma: the Wistar melanoma (WM) cell lines, In Masters, J. R. W., Palsson, B., Eds.,Human Cell Culture, Vol. 3, Kluwer Acad. Publ., London 2000, pp. 259-274.

42. Herlyn, M., Berking, C., Li, G., Satyamoorthy, K.: Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 10:303-312, 2000. PMID10985664

43. Li, G., Herlyn, M.: Dynamics of intercellular communication during melanoma development. Mol Med Today 6:163-169, 2000. PMID10740255

44. Cascinelli, N., Herlyn, M., Schneeberger, A., Kuwert, C., Slominski, A., Armstrong, C., Belli, F., Lukiewcz, S., Maurer, D., Ansel, J., Stingl, G., Saida, T.: What is the most promising strategy for the treatment of metastasizing melanoma? Exp Dermatol 9:439-451, 2000.


32

45. Herlyn, M., Satyamoorthy, K.: Molecular biology of cutaneous melanoma, In DeVita, V. T. J., Hellman, S., Rosenberg, S. A., Eds.,6th Edition of Cancer: Principles and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia, PA 2000, pp. 2003-2012.

46. Berking, C., Herlyn, M.: Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol 16:669-674, 2001. PMID11332722

47. Satyamoorthy, K., Bogenrieder, T., Herlyn, M.: No longer a molecular black box—new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 7:191-194, 2001. PMID11325619

48. Gruss, C., Herlyn, M.: Role of cadherins and matrixins in melanoma. Curr Opin Oncol 13:117-123, 2001. PMID11224709

49. Berking, C., Herlyn, M.: Experimental inductin of human atypical melanocytic lesions and melanoma in ultraviolet-irradiated human skin grafted to immunodeficient mice, In Nickoloff, B., ed.,Methods in Molecular Medicine: Melanoma: Methods and Protocols, Humana Press, Inc., Totowa, NJ 2001, pp. 71-84.

50. Kamb, A., Herlyn, M.: Malignant melanoma, In Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds.,The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Co., New York 2001, pp. 967-977.

51. Hsu, M.Y., Meier, F., Herlyn, M.: Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70:522-536, 2002. PMID12492494

52. Herlyn, M., Padarathsingh, M., Chin, L., Hendrix, M., Becker, D., Nelson, M., DeClerck, Y., McCarthy, J., Mohla, S.: New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section. Am J Pathol 161:1949-1957, 2002. PMID12414540

53. Bogenrieder, T., Herlyn, M.: Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol 44:1-15, 2002. PMID12398996

54. Satyamoorthy, K., Herlyn, M.: Cellular and molecular biology of human melanoma. Cancer Biol Ther 1:14-17, 2002. PMID12170758

55. Li, G., Satyamoorthy, K., Herlyn, M.: Dynamics of cell interactions and communications during melanoma development. Crit Rev Oral Biol Med 13:62-70, 2002. PMID12097238

56. Ruiter, D., Bogenrieder, T., Elder, D., Herlyn, M.: Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 3:35-43, 2002. PMID11905603

57. Herlyn, M.: Emerging concepts and technologies in melanoma research. Melanoma Res 12:3-8, 2002. PMID11828252

58. Herlyn, M., Guerry, D.: First international melanoma research congress. Cancer Biol Ther 2:721-724, 2003. PMID14688485

59. Smalley, K.S., Herlyn, M.: The great escape: another way for melanoma to leave physiological control? J Invest Dermatol 121:xi-xii, 2003. PMID14632176

60. Bogenrieder, T., Herlyn, M.: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524-6536, 2003. PMID14528277

61. Tuveson, D.A., Weber, B.L., Herlyn, M.: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95-98, 2003. PMID12957284

62. Liu, Z.J., Herlyn, M.: Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell 4:1-2, 2003. PMID12892705

63. Marincola, F.M., Wang, E., Herlyn, M., Seliger, B., Ferrone, S.: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24:335-342, 2003. PMID12810110

64. Li, G., Satyamoorthy, K., Meier, F., Berking, C., Bogenrieder, T., Herlyn, M.: Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22:3162-3171, 2003. PMID12789292

65. Velazquez, O.C., Herlyn, M.: The vascular phenotype of melanoma metastasis. Clin Exp Metastasis 20:229-235, 2003. PMID12741681

66. Satyamoorthy, K., Herlyn, M.: p16INK4A and familial melanoma. Methods Mol Biol 222:185-195, 2003. PMID12710687


33

67. Haass, N.K., Smalley, K.S.M., Herlyn, M.: The role of altered cell-cell communication in melanoma progression. J Mol Histol 35:309-318, 2004. SPRINGER35354

68. Perlis, C., Herlyn, M.: Recent advances in melanoma biology. Oncologist 9:182-187, 2004. PMID15047922

69. Haass, N.K., Smalley, K.S., Li, L., Herlyn, M.: Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 18:150-159, 2005. PMID15892711

70. Meier, F., Schittek, B., Busch, S., Garbe, C., Smalley, K., Satyamoorthy, K., Li, G., Herlyn, M.: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986-3001, 2005. PMID15970553

71. Hsu, M.Y., Rovinsky, S., Penmatcha, S., Herlyn, M., Muirhead, D.: Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 24:251-263, 2005. PMID15986135

72. Hsu, M.Y., Li, L., Herlyn, M.: Cultivation of normal human epidermal melanocytes in the absence of phorbol esters. Methods Mol Med 107:13-28, 2005. PMID15492362

73. Fang, D., Herlyn, M.: The transformed phenotype of melanocytes, In Nordlund, J. I., Boissy, R. E., Hearing, V. J., King, R. A., Oetting, W. S., Ortonne, J.-P., Eds.,The Pigmentary System: Physiology and Pathophysiology, 2nd Edition, Blackwell 2006, pp. 489-496.

74. Herlyn, M.: Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer 118:523-526, 2006. PMID16258898

75. Smalley, K.S., Herlyn, M.: Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 1059:16-25, 2005. PMID16382039

76. Haass, N.K., Herlyn, M.: Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10:153-163, 2005. PMID16358819

77. Smalley, K.S., Lioni, M., Herlyn, M.: Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther 5:1069-1078, 2005. PMID16336098

78. Smalley, K.S., Brafford, P.A., Herlyn, M.: Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 15:451-459, 2005. PMID16043361

79. Smalley, K.S., and Herlyn, M.: Towards the targeted therapy of melanoma. Mini Rev. Med. Chem. 6: 387-393, 2006. PMID16613575

80. Cher, M.L., Towler, D.A., Rafii, S., Rowley, D., Donahue, H.J., Keller, E., Herlyn, M., Cho, E.A., Chung, L. W. K.: Cancer interactions with the bone environment. A workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am. J. Pathol. 168: 1405-1412, 2006. PMID1665160

81. Smalley, K.S.M., Lioni, M., and Herlyn, M.: Life isn’t flat: Taking cancer biology to the next dimension. In Vitro Cellular & Develop. Biol – Animals 42:242-247, 2006. PMID 17163781

82. Lee, J.T. and Herlyn, M.: Microenvironment influences melanoma progression. J. Cell. Biochem. 101: 862-872, 2007. PMID 17171636

83. Smalley, K.S. and Herlyn, M.: In: Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds., The Online metabolic and molecular bases of inherited disease. Enzyclopedia of Cancer, Springer, Heidelberg, Chapter 44: Malignant melanoma, pp 1-27, 2007.

84. Pinnix, C.C., and Herlyn, M.: The many faces of Notch signaling in skin-derived cells. Pigment Cell Res. 20: 458-465, 2007. PMID 17935489

85. Herlyn, M., Halaban, R., Ronai, Z., Schuchter, L., Berwick, M., and Pinkel, D.: Roadmap for new opportunities in melanoma research. Semin. Oncol. 34: 566-576, 2007. PMID 18086289

86. Zabierowski, S. and Herlyn, M.: Role of stem cells in melanoma progression: Hopes for a better treatment. Expert Rev. Dermatol. 2: 191-201, 2007.

87. Lee, J.T., and Herlyn, M.: Old disease, new culprit: tumor stem cells in cancer. J. Cell. Physiol. 213: 603-609, 2007. PMID 17873516

88. Gaddipati, H., and Herlyn, M.: Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 13: 226-228, 2007. PMID 1776275


34

89. Smalley, K.S.M., Lioni, M., Noma, K., Haass, N.K., Herlyn, M.: In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion Drug Discov. 3: 1-10, 2008.

90. Zabierowski, S.E., and Herlyn, M.: Melanoma stem cells: the dark seed of melanoma. J Clin. Oncol. 26:2890-2894, 2008, PMID 18539969

91. Roesch, A., and Herlyn, M.: Melanoma Stem cells. In: Cancer Stem cells, ed. By W. Farrar, Cambridge University Press, pp 31-48, 2010.

92. Santiago-Walker, A., Li, L., Haass, N.K., Herlyn, M: Melanocytes: From morphology to application. Skin Pharmacol Physiol 22: 114-121, 2009. PMID19188759

93. Smalley, K.S.M., Desai, B., Herlyn, M.: Therapeutic targeting of the melanoma stem cell population. Melanoma: translational research and emerging therapies, S.S. Agarwala and V.K Sondak, eds., Informa Healthcare Inc., New York, NY, in press.

94. Haass, N.K., Hoeller, C., Herlyn, M.: Targeting signaling pathways- In the search of melanomas’s Achilles’ heel. In: Regulation of gene expression in the tumor envionment, ed by M. Bar-Eli, Springer, pp 27-42, 2008.

95. Villanueva, J., Herlyn, M.: Melanoma and the tumor microenvironment. Curr. Oncol. Rep. 10: 439-446, 2008. PMID 18706274

96. Smalley, K., Herlyn, M.: Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int. J. Cancer 124: 1245-1250, 2009. PMID 19089923

97. Villanueva, J., Herlyn, M.: Melanoma (version 2.0). In: Enclopedia of Life Sciences (ELS), John Wiley & Sons, (Epub March 15), p1-9, 2009.

98. Santiago-Walker, A., Li, L., Herlyn, M.: Melanocytes: From morphology to application. Skin Pharmacol Physiol 22: 114-121, 2009. PMID 19188759

99. Herlyn, M: Driving in the melanoma landscape. Exp. Dermatol. 18: 506-508, 2009. PMID 19366372

100. Fukunaga-Kalabis, M. Santiago-Walker, A., Herlyn, M.: Matricellular proteins produced by melanocytes and melanomas: In search for functions. Cancer Microenvironment 1: 93-102, 2008. PMID 19308688

101. Zabierowski, S.E., Herlyn, M.: Embryonic stem cells as a model to study melanocyte development. Methods Mol Biol. 584: 301-316, 2010. PMID 19907984

102. Gaddipati, H., Herlyn, M.: Melanoma: Mutations in multiple pathways at the tumor-stroma interface. In: Cancer Genome and Tumor Microenvironment, ed. by A. Thomas-Tikhoenenko, Springer, New York, pp.455-470, 2010.

103. Zabierowski, S.E., Fukunaga-Kalabis, M., Li, L., Herlyn, M.: Dermis-derived stem cells: A source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res 24: 422-429, 2011. PMID 21410654

104. Vultur, A., Villanueva, J., Herlyn, M.: Targeting BRAF in advanced melanoma: A first step towards manageable disease. Clin. Cancer Res.17: 1658-1663, 2011. PMID 21447722

105. Fukunaga-Kalabis, M., Roesch, A., Herlyn, M.: From cancer stem cells to tumor maintainenance cells. J Invest. Dermatol. 131: 1600-1604, 2011. PMID 21654838

106. Villanueva, J., Vultur, A., Herlyn, M.: Resistance to BRAF inhibitors: Unraveling mechanisms and future treatment options. Cancer Res., in press, 2011.

107. Zhang, G., Herlyn, M.: Tumor microenvironment for melanoma cells. In: Melanoma development. Molecular Biology, Genetics, and Clinical Application, ed. by A. Bosserhoff, Springer, WienNew York, pp. 297-308, 2011.

108. Herlyn, M., Villanueva, J.: Sorting through the many opportunities for melanoma research. Pigm. Cell Melanoma Res. Sept. 8 [epub ahead of print], 2011. PMID 21899726

109. Li, L., Fukunaga-Kalabis, M., Herlyn, M.: Isolation and culture of dermal stem cells that differentiate into functional melanocytes. In: Human cell culture protocols. Methods in Molecular Biology, vol. 806, Springer Science + Business Ltd, in press, 2011.

110. Lee, J.T., Herlyn, M.: MEK’ing the most of p53 reactivation therapy in melanoma. J Invest. Dermatol., in press, 2011.


35

Research Publications, non-peer-reviewed: 1. Guerry, D., Alexander, M.A., Fuhrer, J.P., Herlyn, M., Mitchell, K.F.: HLA-DR-dependent autologous

T-cell proliferation induced by cultured primary melanoma, In Seji, M., ed.,Phenotypic Expression in Pigment Cells, University of Tokyo Press, Tokyo, Japan 1981, pp. 547-553.

2. Mach, J.P., Forni, M., Buchegger, F., Carrel, S., Ritschard, J., Donath, A., Herlyn, M., Koprowski, H.: Use of radiolabeled monoclonal antibodies against colon carcinoma for photoscanning detection of tumors in patients, In Raynaud, C., ed.,Nuclear Medicine and Biology IV, Pergamon Press, Paris, France 1982, pp. 2292-2294.

3. Holgersson, J., Karlsson, K.A., Karlsson, P., Ringqvist, M., Stromberg, N., Thurin, J., Blaszczyk, M., Herlyn, M., Steplewski, Z., Koprowski, H.: Mouse monoclonal antibodies with specificity for human melanoma cells are directed against hitherto unknown disialogangliosides, In Chester, M. A., Heinegard, D., Lundblad, A., Svensson, S., Eds.,Glycoconjugates, Rahms, Lund-Ronneby, Sweden 1983, pp. 856-858.

4. Herlyn, M., Blaszczyk, M., Koprowski, H.: Immunodiagnosis of human solid tumors, In Riethmueller, G., Koprowski, H., Kleinst, S. V., Munk, K., Eds.,Genes and Antigens in Cancer Cells. Contr. Oncol. Vol. 19, Karger, Basel, Switzerland 1984, pp. 160-170.

5. DeFreitas, E., Suzuki, H., Herlyn, D., Lubeck, M., Sears, H., Herlyn, M., Koprowski, H.: Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen, In,Curr Top Microbiol Immunol1985, pp. 75-89.

6. Herlyn, M., Koprowski, H.: New tumor markers in human gastrointestinal cancer, In Nakamura, R., Vito, W. R., Tucker, E. S. I., Eds.,Clinical Laboratory Molecular Analyses: New Strategies in Autoimmunity, Cancer and Virology, Grune and Stratton, San Diego, CA 1985, pp. 129-143.

7. Herlyn, M. 1985. Tumor markers in human colorectal carcinoma. In Clinical Laboratory Molecular Analyses: Future Directions, p. 86-92. Scripps Clinic and Research Foundation, San Diego

8. Herlyn, M.: Detection of tumor-associated antigens in sera of patients with early gastrointestinal malignancies, In Chatal, J. F., Danis, M., Eds.,Monoclonal Antibodies in Oncology: Clinical Application, Nouvelles Editions Medicales Francaises, Nantes, France 1985, pp. 21-24.

9. Steplewski, Z., Blaszczyk, M., Herlyn, D., Herlyn, M., Koprowski, H. 1985. Effector cells in ADCC with anti-breast cancer monoclonal antibodies. In Ceriani, R. L., ed., Workshop on Monoclonal Antibodies and Breast Cancer, p. 134-149. Martinus Nijhoff Publishing, San Francisco, CA

10. Herlyn, M., Steplewski, Z., Herlyn, D., Koprowski, H.: CO 17-1A and related monoclonal antibodies: their production and characterization. Hybridoma 5 Suppl 1:S3-10, 1986. PMID3744383

11. Clark, W.H.J., Herlyn, M.: Melanocyte differentiation. Lab Invest 57:600-601, 1987. 12. Herlyn, M., Ross, A.H., Balaban, G., Herlyn, D., Thurin, J., Rodeck, U., Koprowski, H.: Cell biology

of melanoma and nonmalignant melanocytic lesions, In Mackie, R. M., ed.,Pigment Cell: Pathobiology of Melanoma, Karger, Basel, Switzerland 1987, pp. 166-181.

13. Kath, R., Rodeck, U., Menssen, H.D., Mancianti, M.L., Linnenbach, A.J., Elder, D.E., Herlyn, M.: Tumor progression in the human melanocytic system. Anticancer Res 9:865-872, 1989. PMID2554787

14. Mancianti, M.L., Herlyn, M.: Tumor progression in melanoma: the biology of epidermal melanocytes in vitro. Carcinog Compr Surv 11:369-386, 1989. PMID2646021

15. Györfi, T., Rodeck, U., Herlyn, M. 1990. Growth factors in melanoma. In Biological Agents in the Treatment of Melanoma and Other Cancers, p. 501-510, Proceedings of the International Conference, Newcastle, Australia

16. Juhasz, I., Herlyn, M. 1990. Stage-related structures on melanoma cells. In Hersey, P., ed., Biological Agents in the Treatment of Melanoma and Other Cancers, p. 256-267, Proceedings of the International Conference, Newcastle, Australia

17. Rodeck, U., Herlyn, M.: Growth regulation in normal and malignant melanocytes, In Paukovits, W. R., ed.,CRC Uniscience: Growth Regulation and Carcinogenesis, CRC Press, Boca Raton, FL 1990, pp. 243-250.


36

18. Graeven, U., Becker, D., Herlyn, M.: Structural and functional characteristics of human melanoma, In Pretlow, T. G., Pretlow, T. P., Eds.,Biochemical and Molecular Aspects of Selected Cancers, Academic Press, Orlando, FL 1991, pp. 151-176.

19. Herlyn, M., Houghton, A.N.: Biology of melanocytes and melanoma, In Balch, C., Houghton, A., Milton, G., Sober, A., Eds.,Cutaneous Melanoma, Lippincott Co., Philadelphia, PA 1991, pp. 82-92.

20. Litwack, G., Robertson, N.M., Maksymowych, A.B., Herlyn, M.: Vitamin B6 and other inhibitors of glucocorticoid receptor function and cell-death of B16 melanoma cells, In Jacobs, M. M., ed.,Vitamins and Minerals in the Prevention and Treatment of Cancer, CRC Press, Boca Raton, FL 1991, pp. 19-30.

21. Valyi-Nagy, I., Rodeck, U., Kath, R., Mancianti, M.L., Clark, W.H., Herlyn, M.: The human melanocyte system as a model for studies on tumor progression. Basic Life Sci 57:315-326; discussion 326-318, 1991. PMID1814292

22. Houghton, A.N., Herlyn, M., Ferrone, S.: Melanoma antigens, In Balch, C., Houghton, A., Milton, G., Sober, A., Eds., Cutaneous Melanoma, Lippincott Co., Philadelphia, PA 1992, pp. 130-143.

23. Miller, E.J., Herlyn, M.: The basement membrane in benign and malignant melanocytic lesions, In Rabes, H., Peters, P. E., Karger, S., Munk, K., Eds.,Contributions to Oncology, Karger, Basel, Switzerland 1992, pp. 269-282.

24. Herlyn, M.: Molecular biology of the melanoma cell surface - translational opportunities. Hem/Onc Annals 1:251-255, 1993.

25. Györfi, T., Herlyn, M.: Melanocyte and melanoma cell lines, In Hay, R. J., ed.,The Atlas of Human Tumor Cell Lines, Academic Press, San Diego, CA 1994, pp. 413-428.

26. Herlyn, M.: International Melanoma Conference Report: Molecular genetics, immunology and experimental pathology of melanoma. Brisbane, Australia, 6-9 April 1994. Melanoma Res 4:331-336, 1994. PMID7858419

27. Herlyn, M., Schuchter, L.: Gene therapy of melanoma: strategies and perspectives. Skin Cancer J 14:92-93, 1996.

28. Puri, N., Herlyn, M.: Melanoma: effects of growth factors, In Miller, S. J., Maloney, M. E., Eds.,Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment, Blackwell Sci. Inc., Cambridge, MA 1996.

29. Dignat-George, F., Bardin, N., Combes, V., Figarella-Branger, D., Frances, V., Herlyn, M., Johnson, J.P., Lepidi, H., Mutin, M., Vewton, J., Pickl, W.F., Schneemann, M., Simmons, D., Simoni, J., Sampol, J.: CD146 (S-ENDO/Muc18), In Kishimoto, T., Goyert, S., Kikutani, H., Mason, D., Miyasaka, M., Moretta, L., Ohno, T., Okumura, K., Shaw, S., Springer, T. A., Sugamura, H., Sugawara, H., von dem Borne, A. E. G. K., Zola, H., Eds.,Leucocyte Typing VI: White Cell Differentiation Ags, Garland Publishing Inc., New York 1997, pp. 755-759.

30. Steplewski, Z., Blaszczyk, M., Herlyn, D., Herlyn, M., Koprowski, H.: Effector cells in ADCC with anti-breast cancer monoclonal antibodies, In Ceriani, R. L., ed.,Monoclonal Antibodies and Breast Cancer, Martinus Nijhoff Publishing, Hingham, MA 1997, pp. 134-139.

31. Herlyn, M.: Endothelial cells as targets for tumor therapy. J Immunother 22:185, 1999. PMID10335478

32. Berking, C., Herlyn, M.: The role of UV in melanomagenesis, In Ortonne, J.-P., Ballotti, R., Eds.,Mechanisms of Sun Tanning, Martin Dunitz Publ., London 2002, pp. 327-332.

33. Bogenrieder, T., Elder, D.E., Herlyn, M.: Molecular and cellular biology, In Balch, C. M., Houghton, A. N., Sober, A. J., Soong, S.-J., Eds.,Cutaneous Melanoma, 4th Edition, Quality Medical Publ., St. Louis, MO 2003, pp. 713-751.

34. Ruiter, G.J., Herlyn, M.: [Melanoma-stroma interactions and melanoma progression]. J Dtsch. Dermatol Ges. 1:773-776, 2003. German.

35. Smalley, K.S., Herlyn, M.: Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J Invest Dermatol 123:xvi-xvii, 2004. PMID15373800

36. Brafford, P., Herlyn, M.: Gene expression profiling of melanoma cells - searching the haystack. J Transl Med 3:2, 2005. PMID15649323

37. Herlyn, M.: Metatastic melanoma cells. Introduction. Cancer Metastasis Rev 24:193-194, 2005. PMID15986131


37

38. Li, G., Herlyn, M.: Information sharing and collateral damage. Trends Mol Med 11:350-352, 2005. PMID16002338

39. Liu, Z.J., Herlyn, M.: Molecular biology of cutaneous melanoma, In DeVita, V. T. J., Hellman, S., Rosenberg, S. A., Eds.,7th edition of Cancer: Principles and Practice of Oncology, Chapter 38, Lippincott Williams & Wilkins, Philadelphia, PA 2005, pp. 1745-1753.

40. Pinnix, C.C., Kogan, M., Herlyn, M.: Melanoma stem cells: Have we overlooked them? Melanoma Letter 23:3-4, 2005.

41. Lee, J. T. and Herlyn, M.: Preventing Metastasis: A LOX to learn. Cellscience Rev. 3: No. 1, 2006. 42. Lee, J.T. and Herlyn, M: Embryogenesis meets tumorigenesis. Nature Med., 12: 882-884, 2006.

PMID16892028 43. Smalley, K.S.M. and Herlyn, M.: Is knowledge about the genetic and epigenetic alterations in

melanoma a basis for targeted therapy? Exp.Dermatol, 844-845, 2007. 44. Smalley, K.S.M., Herlyn, M., Flaherty, K.T. Targeting BRAF/MEK inhibitors in melanoma therapy:

New hope or another false dawn? Exp. Rev. Derm. 2: 179-190, 2007 45. Herlyn, M.: Farming cells to rebuild skin and melanoma. Cancer Biol. Ther. 6: 467-471, 2007,

PMID17374983 46. Fukunaga-Kalabis, M., Li, L., Herlyn, M.: Three-dimensional culture of human skin. AACR

Educational Book, pp 203-206, 2007 AACR Annual Meeting, April 14-18, 2007. 47. Fukunaga-Kalabis, M. and Herlyn, M.: Unraveling mysteries of the multifunctional protein SPARC. J

Invest. Dermatol. 127: 2497-2498, 2007. PMID 17934501 48. Basu, D., Herlyn, M.: Salmonella Typhimurium and a novel RNA interference vector for cancer gene

therapy. Cancer Biol. Therap. 7: 151-152. 2008. PMID 18347415 49. Zabierowski, S.E., and Herlyn, M.: Learning the ABC’s of melanoma-initiating cells. Cancer Cell 13:

185-187, 2008. PMID 18328422 50. Possik, P., Lee, J.T., Herlyn, M.: Transforming the melanocyte: More than just MAPK.

BioforumEurope 2, 1-3, 2008. 51. Lee J. T., Brafford, P., Herlyn, M.: Unraveling the mysteries of IGF-1 signaling in melanoma. J.

Invest. Dermatol. 128: 1358-1360, 2008. PMID18478012 52. Vultur, A., Herlyn, M.: Cracking the system: melanoma complexitiy demands new therapeutic

approaches. Pig. Cell Mel. Res. 22: 4-5, 2009. PMID 19054340 53. Passague, E., Rafii, S., Herlyn, M.: Cancer stem cells are everywhere. Nature Med. 15: 23, 2009.

PMID 19129778 54. Basu, D., Herlyn, M.: Defining microenvironments within mouse models that enhance tumor

aggressiveness. Cancer Biol. Ther. 8: 4, 2009. PMID19182538 55. Fisher, D.E., Barnhill, R., Hodi, F.S., Herlyn, M., Merlino, G., Medrano, E., Bastian, B., Landi, T.M.,

Sosman, J: Melanoma from bech to bedside: meeting report from the 6th international melanoma research congress. Pigm. Cell Melanoma Res. 23: 14-26. PMID20025711

56. Herlyn, M., Fukunaga-Kalabis, M.: What is a good model for melanoma? J Invest. Dermatol. 130: 911-912, 2010. PMID20231823

57. Santiago-Walker, A., Herlyn, M.: The ups and downs of transcription factors in melanoma. J Natl. Cancer Inst. 102: 1103-1104, 2010. PMID20660367

58. Vultur, A., Villanueva, J., Herlyn, M: BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell 18: 301-302, 2010. PMID20951940

59. Herlyn, M., Nathanson, K.: Taking the guesswork out of uveal melanoma. New Engl. J. Med. 263: 2256-2257, 2010. PMID21083377

60. Herlyn, M.: Boris Bastian. Pigm. Cell. Mel. Res. 23: 834, 2010. PMID 20973934 61. Somasundaram, R., Villanueva, J., Herlyn, M.: Will engineered T cells expressing CD20 scFv

eradicate melanoma? Molecular Therapy 19: 638-640, 2011. PMID21455210 Books: Molecular and cellular biology of melanoma, by Herlyn, M., R. G. Landes Co., Austin, TX, 1993

Patents: 1. Detection of Colorectal Carcinoma


38

U.S. Patent # 4,471,057 Issued: September 11, 1984 Inventors: Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn 2. Lewis Blood Group Phenotype Assay U.S. Patent # 4,607,009 Issued: August 19, 1986 Inventors: Zenon Steplewski, Hilary Koprowski, and Meenhard Herlyn 3. Monoclonal Anti-Ornithine Decarboxylase Antibody and Method of Producing Same U.S. Patent # 4,637,984 Issued: January 20, 1987 Inventors: Thomas O’Brien, Anthony Pegg, and Meenhard Herlyn 4. Diagnostic Method for Detection of Neural Crest Disease U.S. Patent # 4,786,593 Issued: November 22, 1988 Inventors: Alonzo Ross, Hilary Koprowski, and Meenhard Herlyn 5. Monoclonal Antibodies against Melanoma-Associated Antigens and Hybrid Cell Lines

Producing These Antibodies and Use Thereof U.S. Patent # 4,849,509 Issued: July 18, 1989 Inventors: Jan Thurin, Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn 6. Monoclonal Antibody to EGF Receptor U.S. Patent # 5,470,571 Issued: November 28, 1995 Inventors: Meenhard Herlyn and Ulrich Rodeck 7. WT1 Monoclonal Antibodies and Methods of Use Thereof U.S. Patent # 5, 622,835 Issued: April 22, 1997 Inventors: Meenhard Herlyn, Frank Rauscher, Ulrich Rodeck, and Jennifer Morris 8. Methods for inducing localized vascular development and enhancing the repair of a wound

in the mammalian dermis. U.S. Patent # 6,486,133 Issued: November 26, 2002 Inventors: Meenhard Herlyn, Mark Nesbit, and Kapaettu Satyamoorthy 9. Organotypic culture of colon and usage thereof U.S. Patenti # 7,217,570 Issued: May 15, 2007 Inventors: Meenhard Herlyn and Jiri Kalabis 10. Multipotent adult stem cells. U.S. Patenti # 60/671,025 Issued: 2005 Inventors: Xiao-Wei Xu, Hong Yu, Doug Fang, Meenhard Herlyn 11. Methods and Composition for Monitoring Cell Migration and Identifying clinically relevant

cytotoxic T Lymphocyte Activity.


39

U.S. Patent # 7,544,465 Issued: June 9, 2009 Inventors: Dorothee Herlyn, Meenhard Herlyn 12. Method for dedifferentiating melanocytes PCT Application No PCT/US2009/058950 Inventors: Meenhard Herlyn and Susan Zabierowski Sept. 30th, 2009 13. Compositions containing JARID1B inhibitors and methods for treating cancer. PCT Application No: 61/232,069 Inventors: Meenhard Herlyn and Alexander Roesch August 7th, 2009

Documents

Date: 10/6/11 - wistar.org 10.6.11.pdf · Meenhard Herlyn, D.V.M., D.Sc. 2 Cancer Center, Houston, TX 1989-1991 Wistar Institute Associate Professor of Dermatology and Wistar Institute